Antibody-drug conjugates and uses thereof

Polarized antibody-drug conjugates targeting HER2, HER3, or EGFR with pH-dependent activation address the limitations of current ADCs by reducing normal tissue toxicity and enhancing therapeutic efficacy against drug-resistant tumors.

JP2024542217AInactive Publication Date: 2024-11-13CSPC MEGALITH BIOPHARMACEUTICAL CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2024529655
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-17
Filing Date
2022-11-17
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current antibody-drug conjugates (ADCs) face challenges such as high toxicity, narrow therapeutic windows, and on-target toxicity due to widespread antigen expression in both tumor and normal tissues, limiting their efficacy and safety.

Method used

Development of antibody-drug conjugates targeting HER2, HER3, or EGFR with pH-dependent activation, featuring specific antibodies and linker-drug compounds that denature in the tumor microenvironment, reducing normal tissue binding and enhancing therapeutic efficacy.

Benefits of technology

The pH-dependent ADCs demonstrate improved safety by minimizing on-target toxicity in normal tissues while maintaining high efficacy against drug-resistant tumors, expanding the therapeutic window and showing better stability and bystander effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542217000076
    Figure 2024542217000076
  • Figure 2024542217000077
    Figure 2024542217000077
  • Figure 2024542217000078
    Figure 2024542217000078
Patent Text Reader

Abstract

The present invention provides antibody-drug conjugates targeting HER2, HER3, and EGFR, and pharma-ceutically acceptable salts, hydrates, solvates, or isotopic derivatives thereof, as well as methods of use and preparation thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antibody-drug conjugate of a camptothecin derivative having an antitumor effect and uses thereof. [Background technology]

[0002] Antibody-drug conjugates (ADCs) consist of three different components: antibodies, linkers, and drugs. ADC technology is a technology that couples antibodies and drug molecules together via linkers and utilizes the specific targeting of antibodies to transport drug molecules to target tissues, thereby reducing the systemic toxic side effects of drugs, expanding the drug therapeutic window, and enhancing the potential of antibody therapy.

[0003] Camptothecin derivatives, which are antitumor low molecular weight compounds, are known to exhibit antitumor activity as topoisomerase I inhibitors. In response to the demand for camptothecin derivatives with high efficacy and low toxicity, many camptothecin derivatives have been developed via semi-synthesis or total synthesis, and are now in the stage of clinical application and clinical trials.

[0004] The ADC drug DS-8201 developed by Daiichi Sankyo using the cytotoxic drug DXd has a unique mechanism of action that results in a 10-fold increase in activity compared to the common chemotherapy drug irinotecan. In addition, DXd can kill nearby cancer cells after killing the cancer cells that have taken up the ADC, resulting in a "bystander effect", and has a strong ability to penetrate cell membranes, significantly shortening its half-life in the blood, helping to reduce the production of toxic side effects. In addition, the linker has high stability, is not affected by toxic drugs in non-tumor tissues, and is specifically cleaved by lysosomal proteases highly expressed in tumors, and can couple multiple cytotoxic drugs to one antibody molecule to increase the drug-antibody ratio (DAR). A new research direction for the development of ADC drugs is provided.

[0005] [ka]

[0006] WO2020063673A1 and WO2020063676A1 disclose exatecan derivatives and their antibody-drug conjugates, in which the exatecan derivatives exhibit growth inhibitory activity against SK-BR-3 cells and U87 cells.

[0007] Although CN111689980A discloses several exatecan derivatives and their antibody-drug conjugates, the application only describes the cellular activity of the exatecan derivatives and SN38, and according to the described activities, most of the compounds show activity comparable to that of SN38; regarding the antibody-drug conjugates, the antibodies used in the antibody-drug conjugates are not disclosed; and the application only conducts preliminary research on the activity of the exatecan derivatives, and does not disclose their effects in other respects.

[0008] The toxins in ADC drugs are highly toxic, and the therapeutic window after ADC drug formation is also narrow. Daiichi Sankyo's exatecan ADC drug DS-8021 has been successfully commercialized. For HER2 target, DS-8021 provides a form in which eight toxins are bound to a single antibody. However, the drugs designed in subsequent clinical trials for Trop2 target have reduced the drug-antibody binding ratio due to safety concerns. However, the reduction in the number of conjugated drugs simultaneously reduces the therapeutic effect of the ADC drug.

[0009] Prodrugs and ADCs require different enzymes and targets, which results in greater individual discrimination, heterogeneity in patient response to prodrugs, and increased toxicity. To solve the above problems, the inventors have been actively developing highly efficient and low-toxicity antibody-camptothecin derivative ADCs to enhance therapeutic efficacy.

[0010] The epidermal growth factor receptor (HER) family includes four structurally similar receptor molecules, ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4), which belong to receptor tyrosine kinases.

[0011] Epidermal growth factor receptor (EGFR, also known as HER1) is a 1186 amino acid residue transmembrane glycoprotein with a molecular weight of 170 kDa and tyrosine kinase activity. EGFR is expressed in many epithelial tissues, including skin and hair follicles. Under normal conditions, EGFR is a monomer, and upon binding to related ligands such as epidermal growth factor (EGF) and transforming growth factor (TGF-α), it forms homo- or heterodimers, which are phosphorylated and activate various downstream signaling pathways to promote cell proliferation, angiogenesis, metastasis, invasion and apoptosis. Many solid tumors, such as colorectal, head and neck, lung, ovarian, cervical, bladder and esophageal cancers, have been found to overexpress EGFR, making EGFR a good tumor therapeutic target.

[0012] Current anti-EGFR drugs mainly include tyrosine kinase inhibitors (TKIs), anti-EGFR monoclonal antibodies (mAbs), antibody-drug conjugates, etc. TKIs compete with adenosine 5'-triphosphate (ATP) for binding to the intracellular catalytic domain of EGFR, thereby inhibiting the phosphorylation of EGFR itself and downstream signaling. Due to the mutation characteristics of EGFR, the competitive binding mode of EGFR-TKIs has evolved from the first generation of non-selective reversible binding (represented by gefitinib, erlotinib, and icotinib), through the second generation of non-selective irreversible binding (represented by afatinib and dacomitinib), to the third generation of selective irreversible binding (represented by osimertinib and alumonatinib). Although the binding ability of EGFR TKIs is stronger and the selectivity is higher, other rare mutations of EGFR (e.g., chromosome 20 exon insertion mutation) remain a blind spot in treatment, and other treatment methods are required.

[0013] Anti-EGFR monoclonal antibodies or bispecific antibodies block ligand-induced EGFR tyrosine kinase activation by competitively binding with ligands for binding to the EGFR extracellular domain. Monoclonal anti-EGFR drugs approved in Japan include cetuximab and nimotuzumab. Clinical data show that EGFR monoclonal antibodies are therapeutically effective only against KRAS wild-type and do not exhibit tumor-inhibitory activity against KRAS mutants.

[0014] The antibody-drug conjugate is endocytosed by binding to the tumor cell surface EGFR and kills the tumor cells by releasing a small molecule toxin. Currently, MRG003, developed by Miracogen, a part of LEPUBIOPHARMA, is a structure that couples the humanized anti-EGFR monoclonal antibody JMT101 and the microtubule toxin inhibitor MMAE via a degradable mc-Vc-PAB (abbreviated as Vc) linker, and was the first EGFR ADC drug to enter the clinical stage in Japan. Phase Ib clinical results showed that the objective response rate (ORR) in patients with non-small cell lung cancer was 40% (4 / 10) and the ORR in patients with nasopharyngeal carcinoma was 44% (4 / 9), demonstrating good drug efficacy. However, the patients in MRG003 stage Ib had advanced or metastatic colorectal cancer, head and neck squamous cell carcinoma, and nasopharyngeal cancer that were EGFR positive and progressed despite various treatment approaches, but the clinical trial data did not clarify whether MRG003 has efficacy in patients resistant to EGFR-TKI (phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumors.doi.org / 10.1016 / j.annonc.2021.08.1315). To address the EGFR-TKI resistance problem, developing a safe and effective ADC drug is the direction of our research.

[0015] If the antigen targeted by ADC drugs is widely expressed in normal tissues, it is likely to cause target-mediated on-target toxicity, limiting the clinical development of ADC drugs. In order to reduce the on-target toxicity of ADC drugs as much as possible, conditionally activated ADCs are used to reduce target toxicity. The tumor microenvironment has many differences from the normal internal environment of the human body in terms of physicochemical properties, with hypoxia, low pH, and high pressure being prominent features. Due to these characteristics, there is a strong presence of immune inflammatory responses due to growth factors, cytokines, and various proteolytic enzymes in the tumor microenvironment, which is highly favorable for tumor growth, invasion, adhesion, angiogenesis, and anti-radiochemotherapy. Tumors undergo glucose degradation under hypoxic conditions, and large amounts of lactic acid are produced by glycolysis, causing a decrease in pH. Currently, the development of pH-dependent ADC drugs is being applied to clinical trials. BioAtla has two ADC drugs, BA3011 targeting AXL and BA3021 targeting ROR2, in the clinical stage. The initial data released by the company showed no significant target-related toxicity, indicating that pH-dependent antibody technology can reduce the target toxicity of ADC drugs.

[0016] The purpose of pH-dependent antibody denaturation is that after antibody denaturation, the constructed ADC molecule cannot bind to antigens or binds to antigens poorly in healthy tissues or the circulatory system, while maintaining its binding ability to antigens in the tumor microenvironment, thereby reducing the target toxicity of ADC drugs and widening the therapeutic window. Denature of antibodies to develop highly effective and low-toxicity ADC drugs is the direction of our research. Summary of the Invention [Means for solving the problem]

[0017] The present invention provides an antibody-drug conjugate according to Formula I, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof.

[0018] [ka]

[0019] where Ab is an antibody or antigen-binding fragment thereof that targets HER2, HER3, or EGFR; R is C 1-6 alkyl, and n is selected from an integer of 1 to 8 or a decimal point of 1 to 8.

[0020] Furthermore, n is selected from an integer of 4 to 8 or a decimal number of 4 to 8.

[0021] Furthermore, when n is an integer selected from 1 to 8, it may be 1, 2, 3, 4, 5, 6, 7, or 8; when n is an integer selected from 4 to 8, it may be 4, 5, 6, 7, or 8.

[0022] Furthermore, when n is a decimal number, it refers to the average number of linker-drug molecules conjugated per antibody unit.

[0023] In a preferred embodiment of the present invention, R is C 1-3 is selected from alkyl.

[0024] In a preferred embodiment of the invention, R is selected from methyl, ethyl, propyl, isopropyl.

[0025] In a preferred embodiment of the invention, R is selected from methyl.

[0026] The present invention further provides an antibody-drug conjugate represented by Formula Ia or Formula Ib, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer or isotopic derivative thereof.

[0027] [ka]

[0028] In Formula Ia and Formula Ib, Ab, R and n are defined as in Formula I.

[0029] The present invention further provides antibody-drug conjugates represented by Formula I-1, Formula Ia-1, and Formula Ib-1, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof:

[0030] [ka]

[0031] In formula I-1, formula Ia-1 and formula Ib-1, Ab and n are defined as in formula I.

[0032] Another aspect of the invention provides an antibody-drug conjugate having Formula II, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof:

[0033] [ka]

[0034] In the formula, Ab is an antibody targeting HER2, HER3, or EGFR, and n is selected from an integer of 1 to 8 or a decimal point of 1 to 8.

[0035] Furthermore, n is selected from an integer of 4 to 8 or a decimal number of 4 to 8.

[0036] Furthermore, when n is an integer selected from 1 to 8, it may be 1, 2, 3, 4, 5, 6, 7, 8; when n is an integer selected from 4 to 8, it may be 4, 5, 6, 7, 8.

[0037] Furthermore, when n is a decimal number, it refers to the average number of linker-drug molecules conjugated per antibody unit.

[0038] In a preferred embodiment of the present invention, the antibody-drug conjugate, and its pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotopic derivative, when Ab is an antibody or antigen-binding fragment thereof targeting HER2, comprises a heavy chain variable region (HV) and a light chain variable region (LV), the sequence of the heavy chain variable region comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2), and heavy chain complementarity determining region 3 (HCDR3), and the sequence of the light chain variable region comprises It comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), and the amino acid sequence of HCDR1 is set forth in SEQ ID NO: 1, the amino acid sequence of HCDR2 is set forth in SEQ ID NO: 2, the amino acid sequence of HCDR3 is set forth in SEQ ID NO: 3, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO: 4, the amino acid sequence of LCDR2 is set forth in SEQ ID NO: 5 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO: 6.

[0039] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER2, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the amino acid sequence of the HV is shown in SEQ ID NO:7 and the amino acid sequence of the LV is shown in SEQ ID NO:8.

[0040] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER2, it comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is set forth in SEQ ID NO: 9 and the amino acid sequence of the LC is set forth in SEQ ID NO: 10.

[0041] In a preferred embodiment of the present invention, when the Ab is an antibody or antigen-binding fragment thereof targeting HER3, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the heavy chain variable region sequence comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3), the light chain variable region comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), the amino acid sequence of HCDR1 is set forth in SEQ ID NO: 11, the amino acid sequence of HCDR2 is set forth in SEQ ID NO: 12, the amino acid sequence of HCDR3 is set forth in SEQ ID NO: 13, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO: 14, the amino acid sequence of LCDR2 is set forth in SEQ ID NO: 15 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO: 16.

[0042] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER3, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the amino acid sequence of the HV is shown in SEQ ID NO: 17 and the amino acid sequence of the LV is shown in SEQ ID NO: 18.

[0043] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER3, it comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is set forth in SEQ ID NO: 19 and the amino acid sequence of the LC is set forth in SEQ ID NO: 20.

[0044] In a preferred embodiment of the present invention, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the heavy chain variable region sequence comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3), and the light chain variable region comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), wherein the amino acid sequence of HCDR1 is set forth in SEQ ID NO:21, the amino acid sequence of HCDR2 is set forth in SEQ ID NO:22, the amino acid sequence of HCDR3 is set forth in SEQ ID NO:23, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO:24, the amino acid sequence of LCDR2 is set forth in SEQ ID NO:25 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO:26.

[0045] In a preferred embodiment of the present invention, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the amino acid sequence of HCDR1 is set forth in SEQ ID NO: 31 or SEQ ID NO: 35 or SEQ ID NO: 38, the amino acid sequence of HCDR2 is set forth in SEQ ID NO: 22, the amino acid sequence of HCDR3 is set forth in SEQ ID NO: 23 or SEQ ID NO: 32, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO: 24, the amino acid sequence of LCDR2 is set forth in SEQ ID NO: 25, and the amino acid sequence of LCDR3 is set forth in SEQ ID NO: 26.

[0046] In a preferred embodiment of the present invention, when the Ab is an antibody or an antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), and the amino acid sequence of HCDR1 is set forth in SEQ ID NO: 31 or SEQ ID NO: 35 or SEQ ID NO: 38, the amino acid sequence of HCDR2 is set forth in SEQ ID NO: 22, the amino acid sequence of HCDR3 is set forth in SEQ ID NO: 32, and the amino acid sequence of LCDR1 is set forth in SEQ ID NO: 24, the amino acid sequence of LCDR2 is set forth in SEQ ID NO: 25, and the amino acid sequence of LCDR3 is set forth in SEQ ID NO: 26.

[0047] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the amino acid sequence of the HV is set forth in SEQ ID NO:27 and the amino acid sequence of the LV is set forth in SEQ ID NO:28.

[0048] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), wherein the amino acid sequence of the HV is set forth in SEQ ID NO: 33, SEQ ID NO: 36, or SEQ ID NO: 39, and the amino acid sequence of the LV is set forth in SEQ ID NO: 28.

[0049] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is set forth in SEQ ID NO:29 and the amino acid sequence of the LC is set forth in SEQ ID NO:30.

[0050] More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain (HC) and a light chain (LC), wherein the amino acid sequence of the HC is set forth in SEQ ID NO:34 or SEQ ID NO:37 or SEQ ID NO:40, and the amino acid sequence of the LC is set forth in SEQ ID NO:30.

[0051] When the Ab is an antibody targeting HER2, HER3 or EGFR, the antibody is preferably a monoclonal antibody, and the monoclonal antibody is preferably selected from a human antibody, a humanized antibody, and a chimeric antibody.

[0052] When the Ab is an antigen-binding fragment targeting HER2, HER3 or EGFR, the antigen-binding fragment is preferably selected from a Fab', (Fab')2, Fab, Fv, scFv, dAb.

[0053] In the present invention, the amino acid sequences of the antibodies are numbered according to the Kabat numbering convention.

[0054] The present invention also provides any of the above antibodies (Abs) or antigen-binding fragments thereof that are unconjugated.

[0055] In addition, the present invention provides the following antibody-drug conjugates, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof:

[0056] [ka] [ka] [ka] [ka] [ka] [ka]

[0057] In the above antibody-drug conjugate, DP001 is an antibody having a heavy chain with two amino acid sequences shown in SEQ ID NO:9 and a light chain with two amino acid sequences shown in SEQ ID NO:10; Patritumab is an antibody having two heavy chains having the amino acid sequences shown in SEQ ID NO: 19 and two light chains having the amino acid sequences shown in SEQ ID NO: 20; SWY2110 is an antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO:29 and a light chain having two amino acid sequences shown in SEQ ID NO:30; SWY2111 is an antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 34 and a light chain having two amino acid sequences shown in SEQ ID NO: 30; SWY2112 is an antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 37 and a light chain having two amino acid sequences shown in SEQ ID NO: 30; SWY2113 is an antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 40 and a light chain having two amino acid sequences shown in SEQ ID NO: 30; n is selected from integers of 1 to 8 or decimals of 1 to 8.

[0058] Furthermore, n is selected from an integer of 4 to 8 or a decimal number of 4 to 8.

[0059] Furthermore, when n is an integer selected from 1 to 8, it may be 1, 2, 3, 4, 5, 6, 7, 8; when n is an integer selected from 4 to 8, it may be 4, 5, 6, 7, 8.

[0060] Another aspect of the present invention provides linker-drug compounds represented by Formula III, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof:

[0061] [ka] where R is defined as in Formula I.

[0062] The present invention further provides linker-drug compounds represented by formula IIIa and IIIb, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof: [ka]

[0063] In formulae IIIa and IIIb, R has the same meaning as in formula III.

[0064] The present invention further provides linker-drug compounds having the formula: and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof:

[0065] [ka]

[0066] The present invention further provides pharmaceutical compositions comprising the antibody-drug conjugates of the present invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof, said pharmaceutical compositions further comprising pharma- ceutically acceptable excipients and carriers.

[0067] The invention provides the use of an antibody-drug conjugate of the invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof, in the manufacture of a medicament for the treatment of a proliferative disease. The proliferative disease is preferably a disease associated with abnormal expression of HER2, HER3 or EGFR, and is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, or lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, or recurrent anaplastic large cell lymphoma).

[0068] The present invention provides a method for treating or preventing a proliferative disease, comprising administering to a patient in need thereof a therapeutically effective amount of the antibody-drug conjugate of the present invention, or a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer or isotopic derivative thereof, or a pharmaceutical composition comprising same, wherein the proliferative disease is preferably a disease associated with abnormal expression of HER2, HER3 or EGFR, including cancer. The cancer is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, or lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, or recurrent anaplastic large cell lymphoma).

[0069] The present invention provides the use of the antibody-drug conjugate of the present invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof, in the manufacture of a medicament for the treatment of a drug-resistant proliferative disease, the drug-resistant proliferative disease being a disease associated with the aberrant expression of HER2, HER3, or EGFR, including cancer, that has resulted in drug resistance. The cancer in which drug resistance has occurred is preferably a drug-resistant cancer caused by HER2, HER3 or EGFR gene mutation, and the cancer is preferably selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, or lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, or recurrent anaplastic large cell lymphoma), and more preferably colon cancer, rectal cancer, lung cancer, or pancreatic cancer. Here, the drug resistance is preferably resistance to receptor tyrosine kinase inhibitors, more preferably resistance to first, second or third generation EGFR inhibitors, even more preferably resistance to gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib or alumonatinib, and more preferably resistance to gefitinib, afatinib, osimertinib or alumonatinib, and more preferably resistance to gefitinib or osimertinib.

[0070] The present invention provides a method for treating or preventing a proliferative disease that has developed drug resistance, comprising administering to a patient in need thereof a therapeutically effective amount of the antibody-drug conjugate of the present invention, or a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer or isotopic derivative thereof, or a pharmaceutical composition comprising the same. The proliferative disease that has developed resistance is a disease associated with the abnormal expression of HER2, HER3 or EGFR that has developed drug resistance, including cancer. The cancer in which drug resistance has occurred is preferably a drug-resistant cancer caused by HER2, HER3 or EGFR gene mutation, and the cancer is preferably selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g., small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g., acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer, or lymphoma (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, or recurrent anaplastic large cell lymphoma), and more preferably colon cancer, rectal cancer, lung cancer, or pancreatic cancer. Here, the drug resistance is preferably resistance to receptor tyrosine kinase inhibitors, more preferably resistance to first, second or third generation EGFR inhibitors, even more preferably resistance to gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib or alumonatinib, particularly resistance to gefitinib, afatinib, osimertinib or alumonatinib, more preferably resistance to gefitinib or osimertinib.

[0071] The present invention provides the use of the linker-drug compounds of the invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, or isotopic derivatives thereof, in the preparation of antibody-drug conjugates.

[0072] The antibody-drug conjugate of the present invention may be used alone or in combination with other anti-tumor agents.

[0073] The present invention further provides pharmaceutical compositions comprising the antibody-drug conjugates of the present invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, and other anti-tumor agents.

[0074] The present invention provides a method for producing the antibody-drug conjugates of the present invention, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, the method comprising the steps of:

[0075] S1: Antibody reduction Specifically, the antibody medium was replaced with PBS6.0 / EDTA, and the antibody concentration was adjusted to 10 mg / mL. Depending on the amount of reduction, appropriate amounts of 10 mM TCEP aqueous solution and 1 M dipotassium hydrogen phosphate aqueous solution were added, and after confirming that the pH of the solution was correct, the solution was incubated at 37°C for several hours to reduce the disulfide bonds in the antibody.

[0076] S2: Linker - Coupling of antibody to drug compound Specifically, 10 mM of the compound dissolved in dimethyl sulfoxide solution is added to the above solution at room temperature, mixed uniformly, and reacted at room temperature for 0.5 to 4 hours to bind the linker-drug compound to the antibody. Then, 100 mM of NAC aqueous solution is added, and the reaction is terminated by further stirring at room temperature.

[0077] S3: Purification of antibody-drug conjugates Specifically, the reaction solution is purified by ultrafiltration using an ultrafiltration centrifuge tube. 25 Mm 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) is added as a purification buffer to the reaction solution, the solution is concentrated to 1-2 mL, and the purification buffer is added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate is obtained.

[0078] The antibody-drug conjugate of the present invention shows a better anti-cell proliferation effect, a significant tumor inhibitory effect, and a better inhibitory activity than DS-8201 against drug-resistant tumors caused by mutations in the HER2, HER3 or EGFR genes, especially against tumors resistant to antitumor agents such as receptor tyrosine kinase inhibitors, and has better stability, such as plasma stability and buffer stability, lower toxicity, better bystander effect, and a wider therapeutic window. The present invention shows that the ADC obtained after denaturing the antibody in a pH-dependent manner and binding the denatured antibody to a linker-drug compound has the same tumor inhibitory activity as the original ADC in terms of efficacy, and has reduced on-target toxicity to normal tissues in terms of safety, and the ADC obtained after optimizing the antibody further expands the therapeutic window.

[0079] definition The term "antibody-drug conjugate," unless otherwise specified, refers to the linking of an antibody (e.g., a monoclonal antibody) or an antibody fragment to a biologically active cytotoxic drug via a stable chemical linker compound.

[0080] The term "linker-drug compound" refers to the substructure of an "antibody-drug conjugate" consisting of a linker compound and a drug compound, unless otherwise specified.

[0081] The linker-drug compound and the antibody in the present invention are coupled by conventional coupling methods in the art, including lysine coupling, interchain reductive disulfide bridge coupling between light and heavy chains, and directed coupling (Non-Patent Document 1: Beck A, Reichert JM., Antibody-drug conjugates: Present and future; MAbs, 2014, 6: 15-17; Non-Patent Document 2: McCombs JR, Owen S C., Antibody-drug conjugates: design and selection of linker, payload and conjugation chemistry. The AAPS journal, 2015, 17: 339-351). In the present invention, the light chains and the heavy chains are preferably linked by a reducible disulfide bond between the chains, i.e., linked by a reaction of a thiol group (sulfur atom of a cysteine ​​residue) formed by reduction of one or more of the disulfide bond sites between the light chains and the heavy chains (two sites between the heavy chains and two sites between the light chains and the heavy chains).

[0082] The term "alkyl", unless otherwise specified, refers to a monovalent saturated aliphatic hydrocarbon group, straight or branched, containing 1 to 20 carbon atoms, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms (i.e., C 1-10 alkyl group), more preferably 1 to 8 carbon atoms (C 1-8 alkyl group), more preferably having 1 to 6 carbon atoms (i.e., C 1-6 alkyl group), e.g. "C 1-6"Alkyl group" refers to an alkyl group having 1 to 6 carbon atoms in the carbon chain (specifically, 1, 2, 3, 4, 5, or 6). Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, neopentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, n-heptyl, n-octyl, and the like.

[0083] The term "pharmaceutical acceptable salt" or "medicinal salt" refers to a salt that, unless otherwise specified, may be applied within the scope of reasonable medical judgment to contact the tissues of mammals, particularly humans, without undue toxicity, irritation, allergic response, etc., and that corresponds to reasonable benefits / risks; for example, medically acceptable salts of amines, carboxylic acids, and other compounds are well known to those skilled in the art. The salts can be prepared in-situ during the final isolation and purification of the compounds of the invention, or can be prepared by reacting the free base or free acid alone with a suitable reagent.

[0084] The term "isotopic derivative" means that, unless otherwise specified, the compounds of the present invention may exist in isotopically traced or enriched form, containing one or more atoms having an atomic mass or mass number different from the most abundant atom occurring in nature. The isotope may be a radioactive or non-radioactive isotope. The isotope commonly used as an isotope derivative is the hydrogen isotope. 2 H and 3 H, a carbon isotope 11 C. 13 C and 13 C, a chlorine isotope 35 Cl and 37 Cl, a fluorine isotope 18 F, an iodine isotope 123 I and 125 I, a nitrogen isotope 13 N and 15 N, an oxygen isotope15 O. 17 O and 18 O and sulfur isotopes 35 S. These isotope derivative compounds can be used to study the distribution of pharmaceutical molecules in tissues. In particular, 2H and carbon 13C are widely used because they are easy to label and detect. Substitution of heavy isotopes such as deuterium (2H) can increase metabolic stability, extend half-life and reduce doses, providing therapeutic advantages. In general, isotope derivative compounds are synthesized from labeled starting materials by known synthetic techniques in the same manner as nonisotopically derived compounds.

[0085] The term "solvate" refers to a physical association of the compound of the present invention with one or more solvent molecules (whether organic or inorganic), unless otherwise stated. The physical association includes hydrogen bonding. In some cases, for example, when one or more solvent molecules are incorporated into the lattice of a crystalline solid, the solvate can be separated. The solvent molecules in the solvate can be present in an ordered arrangement and / or a disordered arrangement. The solvate can include stoichiometric or non-stoichiometric solvent molecules. "Solvate" includes solvates that can be separated from the solution phase. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are known in the art.

[0086] The term "stereoisomers" refers to compounds that have the same chemical structure, but in which the atoms or groups are arranged in a different way in space, unless otherwise specified. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like. Any resulting mixture of stereoisomers can be separated into pure or substantially pure geometric isomers, enantiomers, diastereomers, depending on the differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization techniques. [Brief description of the drawings]

[0087] [Figure 1] DP001-JSSW-001 DAR value detection results [Diagram 2] DP001-ZW-002 DAR value detection results. [Diagram 3] DP001-JSSW-001 DAR value detection results. [Figure 4] Partitumab-JSSW-001 DAR value detection results. [Diagram 5] Detection results of partitumab-ZW-002 DAR value. [Figure 6] SWY2110-JSSW-001 DAR value detection results. [Figure 7] SWY2111-JSSW-001 DAR value detection results. [Figure 8] SWY2112-JSSW-001 DAR value detection results. [Figure 9] SWY2113-JSSW-001 DAR value detection results. [Figure 10] Partitumab-Dxd DAR value detection results. [Figure 11] SWY2110-Dxd DAR value detection results. [Figure 12] SWY2110-Vc MMAE DAR value detection results. [Figure 13] Effect of DP001-ADC on the volume of tumors xenografted with HER2-expressing human breast cancer JIMT-1 cells in NU / NU mice. [Figure 14] The effect of patritumab-ADC on the volume of tumors transplanted with human lung adenocarcinoma PC9-GR (gefitinib drug-resistant cells) cells in NU / NU mice. [Figure 15] Effect of SWY2110-ADC on the volume of human colorectal cancer DiFi cell-transplanted tumors in NU / NU mice. [Figure 16] The effect of SWY2110-ADC on the volume of tumors transplanted with human lung adenocarcinoma PC9-GR (gefitinib drug-resistant cells) cells in NU / NU mice. [Figure 17]Measurement results of DiFi cell inhibitory activity by SWY2110-ADC. [Figure 18] Measurement results of PC9-GR cell inhibitory activity by SWY2110-ADC. [Figure 19] Bystander effect detection results for DP001-ADC. [Figure 20] The effect of SWY2110-ADC on the volume of tumors implanted with human lung adenocarcinoma, PC9-AR (PC9-Del19 / T790M / C797S, Osimertinib drug-resistant cells) cells in NU / NU mice. [Figure 21] Effects of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC on the volume of human lung adenocarcinoma NCI-H1975 cell-implanted tumors in NU / NU mice. [Figure 22] Effects of SWY2110, SWY2111, SWY2112, and SWY2113 ADCs on tumor volume of human breast cancer MDA-MB-468 cells implanted in NOD-SCID mice. [Figure 23] Effects of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC on the volume of human colorectal cancer DiF cell transplanted tumors in NU / NU mice. [Figure 24] The effects of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC on the volume of human lung adenocarcinoma PC9-GR (gefitinib drug-resistant cells) cell-injected tumors in NU / NU mice. [Diagram 25] Effect of patritumab-ADC on the volume of tumors transplanted with human lung adenocarcinoma PC9-DTC (Del19 / T790M / C797S, Osimertinib drug-resistant cells) cells in NOD-SCID mice. [Figure 26] Effect of patritumab-ADC on the volume of colon cancer SW620 cell-inoculated tumors in NU / NU mice. [Figure 27] Measurement results of DiFi cell inhibitory activity by patritumab-ADC. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0088] Hereinafter, the aspects of the present invention will be described with specific examples. It should be understood that these examples are merely for illustrating the present invention and are not intended to limit the scope of the described aspects of the present invention. Experimental methods for which no specific conditions are described in the examples are carried out under normal conditions or conditions suggested by the manufacturer. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described may be applied to the method of the present invention. The preferred embodiments and materials of the present invention are merely illustrative.

[0089] The compound structure of the present invention is identified by nuclear magnetic resonance (NMR) or / and liquid chromatography / mass spectrometry (LC-MS) or / and liquid chromatography (HPLC). The equipment used for NMR measurement was a Bruker Avance III 400 MHz nuclear magnetic resonance meter, the equipment used for LC-MS was a SHIMADZU LC-20AD-PDA-LCMS-2020, and the equipment used for HPLC was a SHIMADZU LC-20AD-PDA high performance liquid chromatography.

[0090] The starting materials in the examples of the present invention are known, commercially available, or can be synthesized using or according to methods known in the art.

[0091] The antibodies of the present invention can be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or can be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567).

[0092] [Production Example] An antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO:9 and a light chain having two amino acid sequences shown in SEQ ID NO:10 is defined as DP001; An antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 19 and a light chain having two amino acid sequences shown in SEQ ID NO: 20 is defined as Patritumab; An antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO:29 and a light chain having two amino acid sequences shown in SEQ ID NO:30 is defined as SWY2110; An antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 34 and a light chain having two amino acid sequences shown in SEQ ID NO: 30 is defined as SWY2111; An antibody having a heavy chain having two amino acid sequences shown in SEQ ID NO: 37 and a light chain having two amino acid sequences shown in SEQ ID NO: 30 is defined as SWY2112; An antibody having two heavy chains with the amino acid sequences shown in SEQ ID NO: 40 and two light chains with the amino acid sequences shown in SEQ ID NO: 30 is defined as SWY2113.

[0093] Antibody sequence description 1. HER2 antibody DP001 (trastuzumab) Light chain (SEQ ID NO: 10): DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO:9): EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK DP001 HCDR1:GFNIKDTYIH (SEQ ID NO: 1) DP001 HCDR2: RIYPTNGYTRYAD (SEQ ID NO: 2) DP001 HCDR3:WGGDGFYAMDY (SEQ ID NO:3) DP001 LCDR1:RASQDVNTAVA (SEQ ID NO: 4) DP001 LCDR2:SASFLYS (SEQ ID NO:5) DP001 LCDR3:QQHYTTPPT (SEQ ID NO:6) DP001 HV: SEQ ID NO:7 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS DP001 LV: SEQ ID NO:8 DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK

[0094] 2. HER3 antibody patritumab Light Chain (SEQ ID NO: 20): DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKV EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO: 19): QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT HTCPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Patritumab HCDR1:GGSFSGYYWS SEQ ID NO:11 Patritumab HCDR2: EINHSGSTNYNPSLKS SEQ ID NO: 12 Patritumab HCDR3:DKWTWYFDL SEQ ID NO:13 Patritumab LCDR1: RSSQSVLYSSSNRNYLA SEQ ID NO: 14 Patritumab LCDR2:WASTRES SEQ ID NO: 15 Patritumab LCDR3:QQYYSTPRT SEQ ID NO: 16 Patritumab HV: SEQ ID NO: 17 QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVETSKNQFSLKLSSVTAADTAVYYCARDKWTWYFDLWGRGTLVTVSS Patritumab LV: SEQ ID NO: 18 DIEMTQSPDSLAVSLGERATINCRSSQSVLYSSSNRNYLAWYQQNPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPRTFGQGTKVEIK

[0095] 3. EGFR antibody SWY2110 Light Chain (SEQ ID NO:30): EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO:29): QVQLQESGPGLVKPSETLSLTTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SWY2110 HCDR1:NYDVH SEQ ID NO:21 SWY2110 HCDR2:VIWSGGNTDYNTPFTS SEQ ID NO:22 SWY2110 HCDR3:ALDYYDYEFAY SEQ ID NO:23 SWY2110 LCDR1:RASQSIGTNIH SEQ ID NO:24 SWY2110 LCDR2: YASESIS sequence number 25 SWY2110 LCDR3:QQNNEWPTS SEQ ID NO:26 SWY2110 HV: SEQ ID NO:27 QVQLQESGPGLVKPSETLSLTTCTVSGFSLSNYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDYYDYEFAYWGQGTLVTVSS SWY2110 LV: SEQ ID NO:28 EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK

[0096] 4. EGFR antibody SWY2111 Light Chain (SEQ ID NO:30): EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO:34): QVQLQESGPGLVKPSETLSLTTCTVSGFSLSDYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SWY2111 HCDR1:DYDVH SEQ ID NO:31 SWY2111 HCDR2:VIWSGGNTDYNTPFTS SEQ ID NO:22 SWY2111 HCDR3:ALDDYDYEFAY SEQ ID NO:32 SWY2111 LCDR1:RASQSIGTNIH SEQ ID NO:24 SWY2111 LCDR2: YASESIS SEQ ID NO:25 SWY2111 LCDR3:QQNNEWPTS SEQ ID NO:26 SWY2111 HV: SEQ ID NO: 33 QVQLQESGPGLVKPSETLSLTTCTVSGFSLSDYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQGTLVTVSS SWY2111 LV: SEQ ID NO:28 EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK

[0097] 5. EGFR antibody SWY2112 Light Chain (SEQ ID NO:30): EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO:37): QVQLQESGPGLVKPSETLSLTTCTVSGFSLSEYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SWY2112 HCDR1:EYDVH SEQ ID NO:35 SWY2112 HCDR2:VIWSGGNTDYNTPFTS SEQ ID NO:22 SWY2112 HCDR3:ALDDYDYEFAY SEQ ID NO:32 SWY2112 LCDR1:RASQSIGTNIH SEQ ID NO:24 SWY2112 LCDR2: YASESIS sequence number 25 SWY2112 LCDR3:QQNNEWPTS sequence number 26 SWY2112 HV: SEQ ID NO: 36 QVQLQESGPGLVKPSETLSLTTCTVSGFSLSEYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQGTLVTVSS SWY2112 LV: SEQ ID NO:28 EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK

[0098] 6. EGFR antibody SWY2113 Light Chain (SEQ ID NO:30): EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Heavy Chain (SEQ ID NO:40): QVQLQESGPGLVKPSETLSLTTCTVSGFSLSHYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SWY2113 HCDR1:HYDVH SEQ ID NO:38 SWY2113 HCDR2:VIWSGGNTDYNTPFTS SEQ ID NO:22 SWY2113 HCDR3:ALDDYDYEFAY SEQ ID NO:32 SWY2113 LCDR1:RASQSIGTNIH SEQ ID NO:24 SWY2113 LCDR2:YASESIS SEQ ID NO:25 SWY2113 LCDR3:QQNNEWPTS sequence number 26 SWY2113 HV: SEQ ID NO: 39 QVQLQESGPGLVKPSETLSLTTCTVSGFSLSHYDVHWVRQAPGKGLEWLGVIWSGGNTDYNTPFTSRLTISVDTSKNQFSLKLSSVTAADTAVYYCARALDDYDYEFAYWGQGTLVTVSS SWY2113 LV: SEQ ID NO:28 EIVLTQSPDFQSVTPKEKVTITCRASQSIGTNIHWYQQKPDQSPKLLIKYASESISGIPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQNNEWPTSFGQGTKLEIK EXAMPLES

[0099] Example 1 N-((2R,10S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9-10,13,15 hexahydro-1H,12H benzo[de]pyran[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-methyl-1,6,9,12,15-pentaoxo-3-oxa5,8,11,14-tetraazahexadecan-16-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide (JSSW-001)

[0100] [ka]

[0101] Scheme 1: [ka]

[0102] First step: Preparation of compound B2-1: B1-1 (1.0g, 2.28mmol), anhydrous tetrahydrofuran (30mL), toluene (10mL), pyridine (0.5mL), lead tetraacetate (1.83g, 4.12mmol) were added to a 100mL three-neck flask, the solution turned orange, heated to reflux, after 1 hour the solution turned colorless, and a white solid was formed, after 3 hours of reaction the solution was filtered through Celite, the solid was washed with ethyl acetate, and the filtrate was dried on a rotary evaporator. The obtained crude product was purified by column chromatography to obtain a solid (640mg). LC-MS [M + Na] +: m / z 391.1.

[0103] Step 2: Preparation of compound A2-1: A1-1 (2.7g, 30.0 mmol) and N,N-dimethylformamide (30 mL) were added to a 100 mL three-neck flask, followed by potassium carbonate (4.17g, 30.0 mmol) and bromobenzyl (2.4 mL, 20.0 mmol). After reacting at room temperature for 14 hours, the reaction solution was dropped into water, extracted with ethyl acetate, and the organic layer was combined and washed with saturated saline, then the organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was purified by column chromatography (PE / EA=3:1) to obtain 2.61 g of the target compound as a colorless liquid. 1H NMR (400 MHz, CDCl3): δ 7.33-7.41 (m, 5H), 5.21 (s, 2H), 4.29-4.35 (m, 1H), 2.77 (d, J= 5.6 Hz, 1H), 1.44 (d, J= 6.8 Hz, 3H).

[0104] Third step: Preparation of compound A3-1: A2-1 (720 mg, 4.0 mmol), B2-1 (368 mg, 1.0 mmol) and dichloromethane (5 mL) were added to a 100 mL three-neck flask, 4-methylbenzenesulfonic acid pyridine (75 mg, 0.30 mmol) was added, and the reaction solution was heated under reflux overnight. After the reaction was completed, ethyl acetate (20 mL) was added to the reaction solution, which was washed three times with water, dried over anhydrous magnesium sulfate, filtered to remove anhydrous magnesium sulfate, and the solution was concentrated. The resulting crude product was purified using column chromatography (PE / EA=2:1) ​​to obtain a white solid A3-1 (290 mg). LC-MS [M+Na] + : m / z 511.1. 1H NMR (400 MHz, CDCl3): δ 7.77 (d, J= 7.2 Hz, 2H), 7.58 (d, J= 7.6 Hz, 2H), 7.40 (t, J= 7.6 Hz, 2H), 7.26-7.37 (m, 6H), 6.70 (brs, 1H), 5.12-5.30(m, 3H), 4.76-4.89 (m, 2H), 4.45 (d, J= 6.8 Hz, 1H), 4.19-4.27 (m, 2H), 3.69-3.85 (m, 2H), 1.41 (d, J= 6.8Hz, 3H).

[0105] Step 4: Preparation of compound A4-1: A3-1 (291 mg, 0.60 mmol) was placed in a 100 mL three-neck flask and dissolved in tetrahydrofuran:ethyl acetate (4 mL / 2 mL). Pd / C (10% w / w, 60 mg) was added, and the mixture was purged with hydrogen gas three times. After stirring overnight under a hydrogen balloon, the reaction solution was passed through Celite, washed with methanol, and the organic layer was concentrated to obtain product A4-1. LC-MS [M + Na] +: m / z 399.1.

[0106] Step 5: Preparation of compound A6-1: In a 25 ml one-neck flask, A4-1 (50 mg, 0.13 mmol, 1.3 eq), exatecan mesylate (A5-1) (50 mg, 0.049 mmol, 1.0 eq), 2-(7-azobenzotriazo)-N,N,N ',N '-tetramethyluronium hexafluorophosphate (48 mg, 0.13 mmol, 1.3 eq), N,N-diisopropylethylamine (36 mg, 0.28 mmol, The mixture was stirred at room temperature overnight, diluted with ethyl acetate, washed with half-saturated citric acid, then with saline, washed with sodium bicarbonate solution, and washed with saline. The organic layer was dried over anhydrous sodium sulfate, filtered to remove anhydrous sodium sulfate, concentrated, and purified using a prep-TLC development system (DCM / MeOH=15:1) to obtain product A6-1 (56 mg), LC-MS [M + H] +: m / z 816.3.

[0107] Step 6: Preparation of compound A7-1: A6-1 (56 mg, 0.069 mmol), N,N-dimethylformamide (2 ml), and piperidine (12 mg, 0.14 mmol) were added to a 25 ml one-neck flask and stirred for 2 hours. The solution was concentrated to give a white solid. LC-MS [M + H] + : m / z 594.3.

[0108] Seventh step: Preparation of compound JSSW-001: A7-1 (0.069 mmol), C7 (66 mg, 0.14 mmol), 2-(7-azobenzotriazo)-N,N,N ',N '-tetramethyluronium hexafluorophosphate (53 mg, 0.14 mmol), N,N-diisopropylethylamine (36 mg, 0.28 mmol) in N,N-dimethylformamide (2 ml) were dissolved in a 25 ml one-neck flask, stirred at room temperature for 2 hours, diluted with ethyl acetate (30 ml), washed with half-saturated citric acid, then washed with saline, washed with sodium bicarbonate solution, washed with saline, and the organic layer was dried over anhydrous sodium sulfate, filtered to remove anhydrous sodium sulfate, concentrated, and purified using a prep-TLC development system (DCM / MeOH=15:1) to obtain product JSSW-001 (21 mg). LC-MS[M+H]+: m / z 1048. 1H NMR (400 MHz, DMSO-d6): δ 8.63 (t, J= 6.4 Hz, 1H), 8.53 (d, J= 8.8 Hz, 1H), 8.28 (t, J= 6.0 Hz, 1H), 8.03-8.10 (m, 2H), 7.98 (t, J= 6.0 Hz, 1H), 7.77 (d, J= 11.2 Hz, 1H), 7.30 (s, 1H), 7.14-7.25 (m, 5H), 6.99 (s, 2H), 6.51 (s, 1H), 5.56-5.62 (m, 1H), 5.40 (s, 2H), 5.08-5.23 (m, 2H), 4.66-4.71 (m, 1H), 4.42-4.56 (m, 2H), 4.09-4.15 (m, 1H), 3.54-3.76 (m, 7H), 3.09-3.27 (m, 1H), 2.97-3.02 (m, 1H), 2.67-2.77 (m, 1H), 2.38 (s, 3H), 2.16-2.21 (m, 2H), 2.05-2.10 (m, 2H), 1.83-1.89 (m, 2H), 1.37-1.46 (m, 7H), 1.14-1.33 (m, 4H), 0.87 (t, J= 7.2 Hz, 3H).

[0109] Scheme 2: [ka]

[0110] First step: Compound C1-1 (8g, 88.86 mmol) and C2-1 (22.66g, 133.33 mmol) were added to a 250 mL reaction bottle, DMAc (40 mL, 5v / w) was added, the supernatant was stirred, the temperature was controlled at 0-10 ° C, and then DIEA (34.45g, 266.6 mmol) was added dropwise. After the dropwise addition was completed, the temperature was naturally raised to around 25 ° C, and the mixture was stirred at this temperature for 16 hours. The reaction completion of the starting material was monitored by TLC. The reaction solution was poured into 120 mL of ice water, MTBE (40 mL) was added, the mixture was stirred, the mixture was separated, the aqueous phase was extracted four times with MTBE (40 mL × 4), the organic phase was combined, and the organic phase was washed once with 0.5 M hydrochloric acid solution (40 mL), once with water (40 mL), and twice with saturated saline (40 mL × 2), in that order. The mixture was dried over anhydrous sodium sulfate, filtered and concentrated, and then purified by wet column chromatography using a petroleum ether:ethyl acetate = 30:1 → 20:1 → 10:1 system to obtain C3-1 as a pale yellow liquid. LC-MS [M + Na] +: m / z 203

[0111] Step 2: Under nitrogen protection, C4-1 (6 g, 16.29 mmol, 1.0 eq) and C3-1 (3.23 g, 17.92 mmol, 1.1 eq) were dissolved in THF (60 mL, 10 V / w), the temperature was lowered to 10-15°C, TsOH (281 mg, 1.63 mmol, 0.1 eq) was added, and the reaction was carried out at 14-18°C for 4 hours, and the completion of the reaction was monitored by TLC. The reaction mixture was added to ice water (60 mL), extracted with EA (60 mL x 3), the organic phases were combined, washed with saturated aqueous NaHCO3 (60 mL), washed with water (60 mL x 2), washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and the column purification column was flushed and subjected to column chromatography using a system of n-hexane:ethyl acetate = 10:1 → 5:1 → 3:1 → 2:1 → 1:1 to obtain a colorless oil C5-1. LC-MS [M + Na] +: m / z 511

[0112] Step 3: Under a nitrogen atmosphere, C5-1 (2.8 g, 5.74 mmol, 1.0 eq) was dissolved in DMAc (28 mL, 10 V / w), cooled to 14-18°C, DBU (436.6 mg, 2.87 mmol, 0.5 eq) was added dropwise, and the mixture was stirred at this temperature for 1.5 hours. The completion of the reaction was monitored by TLC. The mixture was cooled to 0-10°C, and PPTS (721.23mg, 2.87mmol, 0.5eq), EDCI (1.1g, 5.74mmol, 1.0eq), HOBT (775mg, 5.74mmol, 1.0eq) and C7-1 (2.45g, 4.88mmol, 0.85eq) were added. The mixture was reacted at 0-10°C for 3-4 hours, and the completion of the reaction of C7-1 was monitored by TLC. The reaction mixture was added to ice water (100 mL), and further extracted with 2-methyl THF (100 mL x 3). The organic phases were combined, washed with 0.5 M hydrochloric acid (150 mL x 2), washed with saturated NaHO3 aqueous solution (100 mL x 3), washed with water (100 mL), washed with saturated saline (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated to dryness, and purified by column purification. The mixture was purified by column chromatography using the system DCM → DCM:MeOH = 80: 1 → 60: 1 → 50: 1 → 40: 1 → 30: 1 → 20: 1 to obtain a white foam solid C8-1, 3.1 g (yield 72%). LC-MS [M + Na] +: m / z 772.

[0113] Step 4: Under nitrogen protection, C8-1 (3.1g, 4.14mmol, 1.0eq) was dissolved in DCM (46.5mL, 15V / w), DBU (314.6mg, 2.07mmol, 0.5eq) was added dropwise at room temperature 25-30℃, the reaction was stirred at the same temperature for 16 hours, and the reaction completion was monitored by TLC. The reaction was directly passed through a wet column chromatography, and the column chromatography was passed through a system of DCM→DCM:MeOH=50:1→30:1→20:1→10:1 to obtain a white foamy solid C9-1. LC-MS [M + H]+:m / z528.

[0114] Step 5: Under nitrogen protection, C9-1 (1.7g, 3.2mmol, 1.0eq) was dissolved in water (25.5mL, 15V / w) and t-butanol (8.5mL, 5V / w), stirred and dissolved, replaced with nitrogen once, added Pd / C (0.34g, 20% w / w), replaced with hydrogen three times, hydrogenated at room temperature for 12 hours at 25-30°C, and monitored the completion of the reaction of the raw material by LCMS. The reaction solution was filtered, the filter cake was washed with water (25mL x 2), the filtrate was filtered again, concentrated to remove tert-butanol, and the aqueous phase was directly freeze-dried to obtain 1.5g of white powdery solid C10-1 in 100% yield. LC-MS [M + H] +: m / z 438.

[0115] Step 6: Under nitrogen protection, C10-1 (1.4g, 3.2mmol, 1.0eq) was dissolved in acetonitrile (14mL, 10V / w) and water (28mL, 20V / w), C11-1 (1.86g, 6.097mmol, 1.1eq) was added, dissolved and stirred, then cooled to 0-10°C, DIEA (330.24mg, 2.56mmol) was added dropwise, stirred at the temperature at the end of the dropwise addition for 16 hours, and the reaction of the raw material was confirmed to be complete by LC-MS. Na2HPO4 (260mg) and NaH2PO4 (5.6g) were added to 20mL of water, and the supernatant was stirred to prepare a buffer solution, which was then cooled to 0-5°C. The reaction mixture was poured into the frozen buffer and extracted with DCM / isopropanol = 4 / 1 (50 mL x 4), the organic phases were combined, dried, filtered, concentrated to dryness, and purified by column chromatography using DCM → DCM:MeOH = 50:1 → 30:1 → 20:1 → 15:1 system to obtain a yellow solid C12-1.

[0116] Step 7: Under nitrogen protection, A5-1 (547.4mg, 1.03mmol, 1.0eq) was dissolved in 5% anhydrous sodium sulfate water (6.5mL) and THF (7.8mL), stirred well to stop dissolution, cooled to 0-10℃, NMM (104mg, 1.03mmol, 1.0eq) was added, and the reaction was carried out at this temperature for 1 hour. C12-1 (650mg, 1.03mmol, 1.1eq), EDCI (296.2mg, 1.545mmol, 1.5eq) and 2-oxime cyanoethyl acetate (73.9mg, 0.52mmol, 0.5eq) were added in sequence, and after the addition was completed, the reaction was carried out at 0-10℃ for 4-5 hours, and the completion of the reaction of the raw materials was monitored by TLC. The reaction mixture was added to 0.1M hydrochloric acid (13mL, 20V / w) in an ice bath, extracted with 2-methyl THF (13mL x 3), the organic phases were combined, washed once with 0.05M hydrochloric acid (13mL, 20V / w), washed with water (13mL x 2), dried, filtered, concentrated to dryness, and purified by column chromatography. Column chromatography was performed using a system of DCM → DCM:MeOH = 50:1 → 30:1 → 20:1 → 15:1 → 12:1 to obtain a yellow foamy solid JSSW-001. LC-MS [M + H] +: m / z 1048.

[0117] Example 2 N-((S)-((2R,10S)-10-benzyl-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9-10,13,15 hexahydro-1H,12H benzo[de]pyran[3',4':6,7]indolizino[1,2-b]quinolin-1-yl)amino)-2-methyl-1,9,12,1,15,18-pentaoxo-3,6-dioxa,8,11,14,17-tetraazahexadecan-19-yl)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide (ZW-002)

[0118] [ka]

[0119] Scheme 1: [ka]

[0120] Step 1: Preparation of compound A2-2: A1-2 (4.98g, 30 mmol) and N,N-dimethylformamide (40mL) were added to a 100mL three-neck flask, stirred at 0°C, sodium hydride (1.26g, 31.5 mmol) was added, the reaction solution was stirred for another 30 minutes, then 2-(2-bromoethoxy)tetrahydro-2H-pyran (6.59g, 31.5 mmol) was added, and the reaction was allowed to proceed overnight. After the reaction was completed, water (100 mL) was added to the reaction system to quench the reaction, and then the reaction solution was extracted with ethyl acetate (150 mL×3), the organic layers were combined and washed with saturated saline, the organic layer was dried over anhydrous sodium sulfate, filtered to remove solids, the liquid was concentrated, and purified by column chromatography (PE / EA=10 / 1) to obtain A2-2 (6.39g) as a colorless liquid. LC-MS [M + Na] +: m / z 317.2.

[0121] Step 2: Preparation of compound A3-2: Add A2-2 (760 mg, 2.58 mmol) to a 100 mL three-neck flask and stir with dichloromethane (50 mL), add hydrochloric acid methanol solution (0.01 mL) and stir at room temperature for 1 hour. After the reaction was completed, the product was purified in the reverse direction (HO / ACN=1:1) to obtain the target compound A3-2 (660 mg) as a colorless liquid. 1 H NMR (400 MHz, CDCl3): δ 7.37-7.36 (m, 5H), 5.20 (s, 2H), 4.18 (s, 2H), 3.75 (t, J= 1.6 Hz, 2H), 3.70 (t, J= 1.6 Hz, 2H).

[0122] Step 3: Preparation of compound A5-2: A3-2 (105 mg, 0.5 mmol) and dichloromethane (10 mL) were added to a 100 mL three-neck flask and stirred. A4-2 (61 mg, 0.17 mmol) and 4-methylbenzenesulfonic acid pyridine (13 mg, 0.05 mmol) were added, and the mixture was allowed to react overnight under reflux. After the reaction was completed, ethyl acetate (50 mL) was added to the reaction solution and washed three times with water (20 mL × 3). The organic layer was dried over anhydrous magnesium sulfate, filtered to remove solids, and the organic layer was concentrated to dryness. The crude material obtained was purified by column chromatography (PE / EA=1:1) to obtain the target compound A5-2 (80 mg) as a pale yellow liquid. LC-MS [M + H] +: m / z 519.1.

[0123] Step 4: Preparation of compound A6-2: A5-2 (80 mg, 0.15 mmol), tetrahydrofuran:ethyl acetate (10 mL / 5 mL) and Pd / C (10% w / w, 80 mg) were added to a 100 mL three-neck flask, the reaction was replaced with hydrogen gas three times, and then reacted with hydrogen gas overnight. After the reaction was completed, the reaction solution was passed through diatomaceous earth and rinsed with dichloromethane:methanol = 10:1, and the reaction solution was concentrated to obtain the target compound A6-2 (73 mg). LC-MS [M + Na] +: m / z 451.3.

[0124] Fifth step: preparation of compound A8-2: A6-2 (73 mg, 0.17 mmol), exatecan mesylate (45 mg, 0.085 mmol), 2-(7-azobenzotriazole)-N,N,N ',N '-tetramethyluronium hexafluorophosphate (48 mg, 0.13 mmol), and N,N-diisopropylethylamine (110 mg, 0.85 mmol) were dissolved in N,N-dimethylformamide (2 ml) in a 25 ml one-neck flask, stirred overnight at room temperature, diluted with ethyl acetate, washed with ammonium chloride, and then washed with saline. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and purified using a prep-TLC development system (DCM / MeOH=15:1) to obtain product A8-2 (30 mg). LC-MS [M+H]+: m / z 846.4. 1H NMR (400 MHz, DMSO-d6): δ 8.62 (t, J= 9.2 Hz, 1H), 8.41 (d, J= 12 Hz, 1H), 7.87 (d, J= 10.8 Hz, 2H), 7.78 (d, J= 13.6 Hz, 1H), 7.68 (d, J= 8.4 Hz, 2H), 7.52 (t, J= 8 Hz, 1H), 7.39 (t, J= 6.8 Hz, 2H), 7.32-7.28 (m, 3H), 6.50 (s, 1H), 5.62-5,54 (m, 1H), 5.41 (s, 2H), 5.19 (s, 2H), 4.50-4.44 (m, 2H), 4.27-4.23 (m, 2H), 4.20-4.14 (m, 1H), 4.01 (s, 2H), 3.64-3.57 (m, 4H), 3.53-3.48 (m, 2H), 3.21-3.12 (m, 2H), 2.38 (s, 3H), 2.22-2.13 (m, 2H), 1.88-1.80 (m, 2H), 0.85 (t, J= 7.6 Hz, 3H).

[0125] Step 6: Preparation of compound A9-2: A8-2 (30 mg, 0.036 mmol), N,N-dimethylformamide (2 ml), and piperidine (6 mg, 0.07 mmol) were added to a 25 ml one-neck flask and stirred for 2 hours. The solution was concentrated to give a yellow solid A9-2 (30 mg). LC-MS [M + H] + : m / z 624.3.

[0126] Seventh step: Preparation of compound ZW-002: A9-2 (30 mg, 0.048 mmol), C7 (23 mg, 0.048 mmol), 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (28 mg, 0.072 mmol), and N,N-diisopropylethylamine (31 mg, 0.24 mmol) were added to a 25 ml one-neck flask, dissolved in N,N-dimethylformamide (5 ml), stirred at room temperature for 1 hour, diluted with ethyl acetate (30 ml), washed with ammonium chloride, washed with saline, and the organic layer was dried over anhydrous magnesium sulfate, filtered to remove solids, concentrated, and purified using preparative liquid chromatography to obtain product ZW-002 (4.2 mg). LC-MS [M+H]+: m / z1078.2. 1 H NMR (400 MHz, DMSO-d6): δ 8.46-8.39 (m, 2H), 8.28 (t, J= 5.6 Hz, 1H), 8.11-7.96 (m, 3H), 7.78 (d, J= 10.8 Hz, 1H), 7.29 (s, 1H), 7.20-7.16 (m, 5H), 6.97 (s, 2H), 6.5 (s, 1H), 5.63-5.55 (m, 1H), 5.41 (s, 2H), 5.19 (s, 2H), 4.49-4.42 (m, 3H), 4.01 (s, 2H), 3.74-3.64 (m, 3H), 3.64-3.63 (m, 2H), 3.63-3.40 (m, 2H), 3.34-3.32 (m, 1H), 3.20-3.14 (m, 1H), 3.03-2.98 (dd, J= 5.2 Hz, J= 14.4 Hz, 1H), 2.78-2.73 (m, 1H), 2.38 (s, 3H), 2.24-2.13 (m, 2H), 2.10 (t, J= 7.2 Hz, 2H), 1.91-1.77 (m, 2H), 1.50-1.39 (m, 5H), 1.31-1.12 (m, 6H), 0.85 (t, J= 7.2Hz, 3H).

[0127] Scheme 2: [ka]

[0128] First step: B1-2 (24 g, 169 mmol, 1.0 eq) was dissolved in DMSO (1200 mL, 50 v / v), B2-2 (43.35 g, 253 mmol, 5 eq) was added dropwise with stirring, and the mixture was reacted at room temperature for 16 hours at 20-30 ° C. After the reaction was completed, the reaction solution was poured into ice water (250 mL, 10 v / v), the temperature was controlled at 0-10 ° C., and extracted with EA (300 mL, 12-15 v / v) × 3 times. The organic phase was washed with water (200 mL, 8-10 v / v) × 2 and saturated aqueous sodium chloride solution (150 mL, 6-10 v / v) × 1, respectively, and the organic phase was dried over anhydrous sodium sulfate (50 g), concentrated by filtration, and passed through column chromatography to obtain yellow oil B3-2.

[0129] Step 2: B3-2 (14 g, 66.6 mmol, 1.0 eq) was dissolved in THF (280 mL, 20 v / v), B4-2 (29.47 g, 79.92 mmol, 1.2 eq) and TsOH (1.15 g, 6.66 mmol, 0.1 eq) were added, and the reaction mixture was stirred at room temperature at 20-30° C. for 3 hours. After completion of the reaction, the reaction mixture was poured into a mixture of ice water (500 mL, 35-40 v / v) and EA (500 mL, 35-40 v / v), the aqueous phase was extracted with EA (500 mL, 35-40 v / v) × 3, the organic layer was washed with saturated aqueous NaHCO3 solution (250 mL, 15-20 v / v) and water (250 mL, 15-20 v / v), the organic layer was dried by adding anhydrous sodium sulfate (80 g), concentrated as a yellow oil, and purified by column chromatography to obtain a white solid B5-2.

[0130] Third step: B5-2 (12g, 23.16mmol, 1.0eq) was dissolved in DMAc (240mL, 20v / v), DBU (1.76g, 11.8mmol, 0.5eq) was added dropwise, and the mixture was reacted at 10-15°C for 10 minutes. PPTS (2.91g, 11.8mmol, 0.5eq), HOBt (3.12g, 23.16mmol, 1.0eq), B7-2 (11.6g, 23.16mmol, 1.0eq), EDCI (4.4g, 23.16mmol, 1.0eq) were added, and the mixture was reacted at 10-15°C for 3 hours. After the reaction was completed, the reaction mixture was poured into a mixture of ice water (300mL, 25v / v) and methyltetrahydrofuran (500mL, 40-45v / v) (temperature controlled at 0-10℃), the aqueous phase was extracted with methyltetrahydrofuran (300mL, 25v / v) × 3 times, the organic phase was combined, washed once with saturated NaHCO3 aqueous solution (200mL, 15-20v / v) and water (200mL, 15-20v / v), and the organic phase was dried by adding anhydrous sodium sulfate (100g), the drying agent was removed by filtration, and the filtrate was concentrated in a vacuum at 20-30℃ with a water pump to give a yellow oil, which was then subjected to column chromatography to obtain a white solid B8-2.

[0131] Step 4: B8-2 (13 g, 16.68 mmol, 1.0 eq) was dissolved in ACN (130 mL, 10 v / v), DBU (3.0 g, 20.01 mmol, 1.2 eq) was added dropwise, and the mixture was added at room temperature at 20-30 ° C. and reacted for 60 min. After the reaction was completed, the reaction mixture was cooled to ice water (130 mL, 10 v / v), adjusted to pH = 3-4 with 1 M HCl, extracted with EA (150 mL, 10-15 v / v) × 4 (discarded organic phase), adjusted to pH = 8-9 with saturated aqueous NaHCO3, extracted by adding DCM:isopropanol 4:1 (150 mL, 10-15 v / v) × 4, and the organic phases were combined, dried over anhydrous sodium sulfate (80 g), and concentrated to obtain white solid B9-2.

[0132] Fifth step: B9-2 (5.5 g, 9.86 mmol, 1.0 eq) was dissolved in THF (82.5 mL, 15 v / v) and water (27.5 mL, 5 v / v), 10% Pd / C (0.55 g, weight ratio 0.1) was added, the mixture was protected with hydrogen, and reacted at 20-30°C for 16 hours. Post-reaction treatment 1: Pd / C was filtered off from the reaction solution, and the solution was extracted with water (100 mL, 18-20 v / v) and EA (100 mL, 18-20 v / v) × 2 (the organic phase was discarded), and the aqueous phase was designated as solution A (B10-2). Procedure 2: Solution A (B10-2) (130 mL) was added to a reaction flask, B11-2 (3.6 g, 11.83 mmol, 1.2 eq) was dissolved in ACN (49.5 mL, 9 v / v), DIEA (1.27 g, 9.86 mmol, 1.0 eq) was added dropwise, and the mixture was reacted at 10 to 15°C for 5.0 hours. Reaction workup 2: The reaction mixture was poured into ice water (100 mL, 18-20 v / v), and the aqueous phase was extracted with EA (150 mL, 10-15 v / v) × 3, the water was temperature controlled at 0-10 °C, and the pH was adjusted to 2-3 with 0.5 M HCl, and extracted with DCM:isopropanol 4:1 (150 mL, 10-15 v / v) × 4, and the organic phases were combined and dried over anhydrous sodium sulfate (50 g), and the filtrate was concentrated and pumped dry to obtain a white solid B12-2.

[0133] Step 6: Anhydrous sodium sulfate (0.8g, 0.5v / v), water (16mL, 10v / v), THF (19.2mL, 12v / v) were stirred and A5-1 (1.6g, 3.0mmol, 1.0eq) was added, cooled to 5-10°C, N-methylmorpholine (0.304g, 3.0mmol, 1.0eq) was added dropwise, and the reaction was carried out at 5-10°C for 40 minutes, followed by the addition of B12-2 (2.4g, 3.6mmol, 1.2eq), EDCI (0.863g, 4.5mmol, 1.5eq), and ethyl 2-oxime cyanoacetate (0.214g, 1.5mmol, 0.5eq), and the reaction was carried out at 5-10°C for 3.0 hours. After completion of the reaction, the reaction solution was poured into 150 mL of ice water, extracted with EA (150 mL × 3), washed once each with 0.1 M HCl (50 mL) and water (150 mL), and the organic phase was dried over 30 g of anhydrous sodium sulfate and concentrated to dryness, followed by column chromatography to obtain a pale yellow solid ZW-002.

[0134] Example 3 Antibody-drug conjugate (DP001-JSSW-001 ADC, DAR=4.0) [ka]

[0135] Step 1: Reduction of antibody The medium of the DP001 antibody, which was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (17 μL, 2.5 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 50 μL). After confirming that the pH of this solution was within 7.4 ± 0.1, it was incubated at 37 ° C for 1 hour. This reduced the disulfide bonds in the antibody.

[0136] Step 2: Coupling of the antibody to the linker-drug compound The above solution was added with 10 mM dimethyl sulfoxide solution of JSSW-001 compound obtained in Example 1 (31.28 μL, 4.6 equivalents per antibody molecule) at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0137] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-JSSW-001 ADC, DAR = 4.0) was obtained.

[0138] Step 4. Determination of the Drug-Antibody Conjugate Ratio (DAR): Dithiothreitol was added to 2 mg / kg of antibody-drug conjugate at a final concentration of 20 mM, and the mixture was placed in a water bath at 37°C for 30 minutes to cleave the interchain disulfide bond of the antibody-drug conjugate, and the sample was used for HPLC analysis. The HPLC system used was Agilent Technologies 1260 Infinity HPLC, the column used was PLRP-S (5 μm particle size; 2.1 mm × 50 mm; Agilent Technologies), the column temperature was 80°C, mobile phase A was 0.1% trifluoroacetic acid (TFA) aqueous solution, and mobile phase B was 0.1% trifluoroacetic acid (TFA) acetonitrile solution. The volume of sampling was 10 μL, and the gradient program was 27-27% in 0-3 min, 27-35% in 3-8 min, 35-43% in 8-25 min, 43-95% in 25-26 min, 95-95% in 26-31 min, 95-27% in 31-32 min, and 27-27% in 32-40 min. Compared with the unbound light chain (L0) and heavy chain (H0), the drug-bound light chain (light chain bound with one drug, L1) and heavy chain (heavy chain bound with one drug, H1, heavy chain bound with two drugs, H2, heavy chain bound with three drugs, H3), the hydrophobicity increases as the number of bound drugs increases, and they are eluted in the order of L0, L1, H0, H1, H2, and H3. The DAR values ​​were calculated from the peak areas at 280 nm. The results of the DAR values ​​are shown in Figure 1.

[0139]

number

[0140] Example 4 Antibody-Drug Conjugate (DP001-ZW-002 ADC, DAR=5.78) [ka]

[0141] Step 1: Reduction of antibody The medium of the DP001 antibody, which was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37 ° C for 3 hours. This reduced the disulfide bonds in the antibody.

[0142] Step 2: Coupling of the antibody to the linker-drug compound The above solution was added with 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JZW-002 obtained in Example 2 at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0143] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-ZW-002 ADC, DAR = 5.78) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0144] Example 5 Antibody-Drug Conjugate (DP001-JSSW-001 ADC, DAR=7.32) [ka]

[0145] Step 1: Reduction of antibody The medium of the DP001 antibody, which was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37 ° C for 3 hours. This reduced the disulfide bonds in the antibody.

[0146] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0147] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-JSSW-001 ADC, DAR = 7.32) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0148] Example 6 Antibody-drug conjugate (patritumab-JSSW-001 ADC, DAR=7.36) [ka]

[0149] Step 1: Reduction of antibody Patritumab antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0150] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0151] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-JSSW-001 ADC, DAR = 7.36) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0152] Example 7 Antibody-drug conjugate (patritumab-ZW-002 ADC, DAR=7.45) [ka]

[0153] Step 1: Reduction of antibody Patritumab antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0154] Step 2: Coupling of the antibody to the linker-drug compound The above solution was added with 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JZW-002 obtained in Example 2 at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0155] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-ZW-002 ADC, DAR = 7.45) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0156] Example 8 Antibody-Drug Conjugate (SWY2110-JSSW-001 ADC, DAR=7.12) [ka]

[0157] Step 1: Reduction of antibody SWY2110 antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (66.6 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0±0.1, it was incubated at 37° C. for 3 hours. This reduced the disulfide bonds in the antibody.

[0158] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0159] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, Ultracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). By adding L-histidine 0.89 mg / ml, L-histidine hydrochloride 4.04 mg / ml, Tween 80 0.03%, sucrose 90 mg / ml (pH = 5.5) as a buffer to the reaction solution, unbound linker-drug compound and other low molecular weight reagents were removed, and a purified antibody-drug conjugate (SWY2110-JSSW-001 ADC, DAR = 7.12) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0160] Example 9 Preparation of pH-dependent antibodies Using computer modeling technology, SWY2110 and EGFR protein were modeled and linked to obtain an antigen-antibody complex. Amino acids within 3 Å of the complex were D, E, and H scanned to obtain multiple pH-dependent antibodies that showed reduced affinity at pH 7.4 and substantially maintained or only slightly reduced affinity at pH 6.0. The multiple antibody sequence genes obtained were cloned into mammalian expression vectors, and antibodies were expressed by transfection into HEK-293 cells. After expression, the expression supernatant was collected and the antibodies were purified using AKTA Protein A preloaded column chromatography to obtain the desired antibodies.

[0161] Example 10 Measurement of antibody affinity MDA-MB-468 cells were digested into single cells using 0.25% pancreatin-EDTA, with 10 cells per fraction. 6The cells were averaged over a large number of fractions so that the number of fractions exceeded 1000. 300 μL of 5-fold serially diluted SWY2110 (control) and the antibody obtained in Example 9 (diluted in PBS buffer at pH 7.4 and pH 6.0, respectively) were added to the cells, incubated at 4°C for 1 hour, centrifuged at 1000 rpm for 4 minutes, and the supernatant was removed. After washing twice with PBS solution, 200 μL of FITC-labeled mouse anti-human Fc secondary antibody diluted 1:200 was added, incubated at 4°C for 1 hour, and after the incubation was completed, the supernatant was removed by centrifugation at 1000 rpm for 4 minutes. The fluorescence intensity was detected using a flow cytometer, the data was stored, and the data was analyzed by the associated software. The antibody affinity measurement results after screening are shown in Table 1. The results of measuring the affinity of antibodies for their target antigens after pH-dependent optimization showed that at pH 7.4, the affinity of pH-optimized antibodies SWY2111, SWY2112, and SWY2113 was significantly reduced relative to SWY2110 (approximately 3.0-9.7-fold), whereas at pH 6.0, the affinity of SWY2111 and SWY2112 was almost constant relative to SWY2110 (1.2-1.3-fold), and the degree of decrease in affinity of the SWY2113 antibody was 6.6-fold.

[0162] [Table 1]

[0163] Example 11 Antibody-drug conjugate (SWY2111-JSSW-001 ADC, DAR=7.48) [ka]

[0164] Step 1: Reduction of antibody The medium for the SWY2111 antibody was replaced with PBS6.0 / EDTA to adjust the antibody concentration to 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (66.6 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0165] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0166] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). By adding L-histidine 0.89 mg / ml, L-histidine hydrochloride 4.04 mg / ml, Tween 80 0.03%, sucrose 90 mg / ml (pH = 5.5) as a buffer to the reaction solution, unbound linker-drug compound and other low molecular weight reagents were removed, and a purified antibody-drug conjugate (SWY2111-JSSW-001 ADC, DAR = 7.48) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0167] Example 12 Antibody-drug conjugate (SWY2112-JSSW-001 ADC, DAR=7.51) [ka]

[0168] Step 1: Reduction of antibody The medium for the SWY2112 antibody was replaced with PBS6.0 / EDTA to adjust the antibody concentration to 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (66.6 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0169] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0170] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, Ultracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). By adding L-histidine 0.89 mg / ml, L-histidine hydrochloride 4.04 mg / ml, Tween 80 0.03%, sucrose 90 mg / ml (pH = 5.5) as a buffer to the reaction solution, unbound linker-drug compound and other low molecular weight reagents were removed, and a purified antibody-drug conjugate (SWY2112-JSSW-001 ADC, DAR = 7.51) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0171] Example 13 Antibody-drug conjugate (SWY2113-JSSW-001 ADC, DAR=7.50) [ka]

[0172] Step 1: Reduction of antibody The medium for the SWY2113 antibody was replaced with PBS6.0 / EDTA to adjust the antibody concentration to 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (66.6 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0173] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of JSSW-001 obtained in Example 1 was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0174] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, Ultracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). By adding L-histidine 0.89 mg / ml, L-histidine hydrochloride 4.04 mg / ml, Tween 80 0.03%, sucrose 90 mg / ml (pH = 5.5) as a buffer to the reaction solution, unbound linker-drug compound and other low molecular weight reagents were removed, and a purified antibody-drug conjugate (SWY2113-JSSW-001 ADC, DAR = 7.50) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0175] Reference Example 1 Antibody-drug conjugate (DP001-DXD ADC, DAR=4.3) [ka]

[0176] Step 1: Reduction of antibody The medium of the DP001 antibody, which was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (17 μL, 2.5 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 50 μL). After confirming that the pH of this solution was within 7.4 ± 0.1, it was incubated at 37 ° C for 1 hour. This reduced the disulfide bonds in the antibody.

[0177] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM of commercially available Deruxtecan (CAS No.: 1599440-13-7) in dimethyl sulfoxide (31.28 μL, 4.6 equivalents per antibody molecule) was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM of NAC (J&K Scientific) in water (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0178] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-DXD ADC, DAR = 4.3) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3.

[0179] Reference Example 2 Antibody-drug conjugate (DP001-DXD ADC, DAR=7.0) [ka]

[0180] Step 1: Reduction of antibody The medium of the DP001 antibody, which was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37 ° C for 1 hour. This reduced the disulfide bonds in the antibody.

[0181] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of commercially available Deruxtecan (CAS No.: 1599440-13-7) was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0182] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (DP001-DXD ADC, DAR = 7.0) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3.

[0183] Reference Example 3 Antibody-drug conjugate (patritumab-DXD ADC, DAR=7.3) [ka]

[0184] Step 1: Reduction of antibody Patritumab antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 100 mM TCEP (J&K Scientific) aqueous solution (6.66 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU, 18 μL). After confirming that the pH of this solution was within 7.0 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0185] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of commercially available Deruxtecan (CAS No.: 1599440-13-7) was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0186] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, μLtracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (patritumab-DXD ADC, DAR = 7.3) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0187] Reference Example 4 Antibody-drug conjugate (SWY2110-DXD ADC, DAR=6.93) [ka]

[0188] Step 1: Reduction of antibody SWY2110 antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (66.6 μL, 10 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU). After confirming that the pH of this solution was within 7.0±0.1, it was incubated at 37° C. for 3 hours. This reduced the disulfide bonds in the antibody.

[0189] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (87 μL, 13 equivalents per antibody molecule) of commercially available Deruxtecan (CAS No.: 1599440-13-7) was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0190] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, Ultracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (SWY2110-DXD ADC, DAR = 6.93) was obtained. The method for measuring the DAR value was the same as in the fourth step of Example 3, and the results of the DAR value are shown in FIG.

[0191] Reference Example 5 Antibody-drug conjugate (SWY2110-VC MMAE ADC, DAR=4.53) [ka]

[0192] Step 1: Reduction of antibody SWY2110 antibody was expressed and purified in HEK293 cells transiently transfected with plasmids encoding light and heavy chain genes by a known technique, and the medium was replaced with PBS6.0 / EDTA to prepare an antibody concentration of 10 mg / mL. This solution (1.0 mL) was placed in a 1.5 mL polypropylene tube, to which was added a 10 mM TCEP (J&K Scientific) aqueous solution (17 μL, 2.5 equivalents per antibody molecule) and a 1 M dipotassium hydrogen phosphate aqueous solution (TianJin GUANG FU). After confirming that the pH of this solution was within 7.4 ± 0.1, it was incubated at 37°C for 3 hours. This reduced the disulfide bonds in the antibody.

[0193] Step 2: Coupling of the antibody to the linker-drug compound To the above solution, 10 mM dimethyl sulfoxide solution (31.28 μL, 4.6 equivalents per antibody molecule) of commercially available mc-Vc-PAB-MMAE (CAS No.: 646502-53-6, abbreviated as VcMMAE) was added at room temperature, mixed uniformly, and reacted at room temperature for 30 minutes to bind the linker-drug compound to the antibody. Next, 100 mM NAC (J&K Scientific) aqueous solution (10.2 μL) was added, and the mixture was stirred at room temperature for another 20 minutes to terminate the reaction.

[0194] Step 3: Purification of antibody-drug conjugate The reaction solution was purified by ultrafiltration using an ultrafiltration centrifuge tube (Merck, Ultracel® Regenerated CellμLose (30 kDa MWCO), 15 mL sample volume). 25 mM 2-(N-morpholine)ethanesulfonic acid (MES) (pH = 6.5) was added to the reaction solution as a purification buffer, the solution was concentrated to 1-2 mL, and the purification buffer was added again at a substitution ratio of more than 1000 times to remove unbound linker-drug compounds and other low molecular weight reagents, and a purified antibody-drug conjugate (SWY2110-VC MMAE ADC, DAR = 4.53) was obtained.

[0195] Step 4. Determination of Drug-Antibody Conjugate Ratio (DAR) of the Antibody-Drug Conjugate: 10 μg of SWY2110-Vc MMAE ADC sample was taken and applied to column chromatography (2.5 μM particle size; 4.6 mm × 10 cm TSKgel Butyl-NPR) with eluents of 20 mM PB, pH 7.0, 1.5 M (NH4)2SO4 aqueous solution, and 20 mM PB, pH 7.0, 25% isopropanol solution, at a flow rate of 0.8 mL / min, column temperature of 30 °C, and detection wavelength of 280 nm. The gradient was 0-20 min, 0-100% mobile phase B, 20-25 min, 100% mobile phase B, and 25-30 min, 100% mobile phase A. Unbound was DAR0, 2 small molecule bound was DAR2, 4 small molecule bound was DAR4, 6 small molecule bound was DAR6, and 8 small molecule bound was DAR8. Therefore, the elution order was DAR0, DAR2, DAR4, DAR6, and DAR8. The DAR values ​​were calculated from the peak areas at 280 nm, and A represented the percentage of each peak area. The results of the DAR values ​​are shown in FIG. 12. DAR=2×ADAR2+4×ADAR4+6×ADAR6+8×ADAR8

[0196] Biological Examples Test 1: In vitro antibody-drug activity 1. Test purpose: The purpose of this test is to detect the in vitro inhibitory activity of the antibody-drug conjugate of the present invention against SK-BR-3 (ATCC / HTB-30) tumor cells, human colorectal cancer cells DiFi, human lung cancer gefitinib-resistant cells PC9-GR, and human lung cancer mutant cells PC-9 (Del19-T790M-C797S) tumor cells. After treating the cells in vitro at various concentrations and culturing, Resazurin was added and the fluorescence value at ex550nm / em610nm was read, and the IC50 value was derived from the four-parameter fit processing data, thereby calculating the biological activity of the compound.

[0197] 2. Test materials and equipment: [Table 2]

[0198] 3. Test operation method 1: 3.1 Medium: DMEM, 10% FBS, 1x bispecific antibody 3.2. Cell culture: Remove one frozen SK-BR-3 / MDA-MB-468 cell from liquid nitrogen and place it in a 75cm 2 The cells were resuscitated in a culture flask and cultured until they reached 75% or more confluence and were passaged at least three times. 3.2.1 If the cells were not passaged, the medium was changed every 3 to 4 days. 3.2.2 If cell expansion is required, passage the cells into larger culture flasks and allow the cells to be >75% confluent before use in the assay. 3.3 Harvesting cells: SK-BR-3 / MDA-MB-468 cells were harvested when the culture flasks were nearly full. 3.3.1 The medium was discarded and dead cells and residual medium were removed with a PBS wash. 3.3.2 2-3 mL of 0.25% Trypsin-EDTA was added, the culture flask was gently rocked, and then incubated at 37° C. for 2-3 minutes to digest the cells. 3.3.3 Immediately add 5 mL of medium to the culture bottle and gently pipette up and down to disperse the cells. 3.3.4 The cell suspension was transferred to a sterile centrifuge tube and centrifuged at 200 x g for 3 minutes. 3.3.5 Discard the medium in the tube and add 5 to 10 mL of fresh culture medium to resuspend the cells. 3.4 Cell density measurement: The cells were counted using a cell counting plate under a microscope. 3.5 Analysis Plate Inoculation 3.5.1 Cells were cultured at 1 x 10 in medium. 5 cells / mL and seeded into the assay plate at 100 μL / well (except rows A and H). 3.5.2 As a control, 120 μL of medium was added to each well in rows A and H. 3.5.3 Incubate at 37℃, 5% CO2 for 4 to 6 hours to allow the cells to adhere to the wall. 3.6 Preparation of diluted compound samples Compounds were diluted to an initial concentration of 18 μg / ml and further diluted 3-fold to give a total of 11 solutions, with column 12 being a control. 3.7 Drug Addition 3.7.1 20 μL of the drug dilutions in columns 1 to 11 of the dilution plate were dispensed and added to columns 1 to 11 of the analysis plate, respectively. 3.7.2 20 μL of fresh medium was added to column 12 and rows A and H. 3.7.4 Gently shake on a plate shaker for 10-15 seconds, then incubate the culture plate at 37 °C for 3 days. 3.8 Analysis 3.8.1 After the incubation was completed, add 20 μL of 0.03% resazurin (diluted in 1x PBS) per well and shake gently for 10-15 seconds. 3.8.2 After 3-4 hours of incubation at 37°C, the plate reader was read and the parameters were as follows: Excitation light: 550 nm Emitted light: 610nm Integration time: 50 Concussion: 15 seconds, vortex Reading:Read above Number of reads / well: 1 Gain: Optimize settings (between 35 and 42) When reading multiple plates, it was ensured that the gain settings used for all plates were uniform. 3.8.3 Using the EXCEL data, calculate the IC of the reference standard and samples 50 The fitting was performed as follows. 3.8.3.1 Model 201 was used to plot the data points. 3.8.3.2 For the Fit parameter, the following command was used: A: Pre-dispense b. B: Pre-dispense c. C: Pre-dispense d. D: Pre-dispense e. Not all constraints 3.8.3.3 Parameter C as IC 50 was output as. The results are shown in Table 1.

[0199] Test procedure 2: This study demonstrated the proliferation inhibition of two cell lines, DiFi (human colorectal cancer cells) and PC9-GR (human lung cancer gefitinib-resistant cells), by SWY2110 monoclonal antibody (SWY2110 mAb), SWY2110-DXD ADC (DAR=6.93), and SWY2110-JSSW-001 ADC (DAR=7.12), with the specific concentrations set as follows:

[0200] DiFi:SWY2110 mAb, SWY2110-DXD ADC (DAR=6.93) and SWY2110-JSSW-001ADC (DAR=7.12) were diluted in triplicate starting at 3000 ng / ml for a total of 10 concentrations: 3000, 1000, 333.33, 111.11, 37.04, 12.35, 4.12, 1.37, 0.46 and 0.15 ng / ml, respectively, and incubated for 144 h.

[0201] PC9-GR:SWY2110 mAb, SWY2110-DXD ADC (DAR=6.93), and SWY2110-JSSW-001 ADC (DAR=7.12) were diluted stepwise from a starting concentration of 1000 ng / ml to eight concentrations: 1000, 200, 40, 8, 1.6, 0.32, 0.64, and 0.013 ng / ml, respectively, and incubated for 144 h.

[0202] Cells in logarithmic growth phase were seeded in a fixed amount in a 96-well plate (100 μL / well), and 24 h after the cells adhered to the wall, 100 μL of culture medium with different concentration gradients of SWY2110 mAb, SWY2110-DXD ADC (DAR=6.93) or SWY2110-JSSW-001 ADC (DAR=7.12) was added to each well on that day, and three duplicate wells were set for each drug concentration, and corresponding blank wells (medium only) and normal wells (drug concentration 0) were set. After 144 hours of drug action, 20 μL of MTT working solution (5 mg / mL) was added per well for 4 hours at 37 °C, the supernatant was shaken off, and 150 μL of DMSO (analysis pure) was added. The plates were shaken and mixed on a microwell shaker, the plates were wiped clean, and the optical density values ​​(OD) were measured with a microplate reader at 550 nm. The inhibition rate of cell proliferation was calculated using the following formula: Inhibition rate (%) = (OD value 正常孔 -OD value 投与孔 ) / (OD value 正常孔 -OD value 空白孔 )×100% Drug half inhibitory concentration IC 50 was calculated from the inhibition rate at each concentration using SPSS 19.0. The results are shown in Tables 2 and 3 and in Figures 17 and 18.

[0203] Test data: [Table 3] From the data presented in Table 2, the antibody-drug conjugate of the present invention, DP001-JSSW-001 ADC (DAR=7.12), had a lower IC against SK-BR-3 cells than DP001-DXD ADC (DAR=6.93). 50 It has been found that the α-aminobutyric acid α-succinic acid (ASA) had better anti-cell proliferation effects. [Table 4] From the data in Table 3, the antibody-drug conjugate SWY2110-JSSW-001 ADC (DAR=7.12) of the present invention, like the SWY2110-DXD ADC (DAR=6.93), showed similar IC against the EGFR highly expressing cell line DiFi and the gefitinib resistant cell line PC9-GR. 50 and showed superior anti-cell proliferation effects than SWY2110 mAb.

[0204] Study 2: Efficacy study of antibody-drug conjugates against HER2-expressing human breast cancer JIMT-1 cell-implanted tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 24 mice

[0205] 2. Purpose of the study The in vivo antitumor effect of the antibody-drug conjugate was examined using a HER2-expressing human breast cancer JIMT-1 cell xenograft tumor model in NU / NU mice.

[0206] 3. Drug Dosage and Grouping [Table 5]

[0207] 4. Test Method In this study, a nude mouse tumor model was constructed using human breast cancer cells, JIMT-1, and the tumor volume was approximately 127 mm 3 When the tumor volume reached 100 mg / kg, the animals were divided into 4 groups (d0) on average according to the tumor volume as shown in Table 4, and the drug was administered intravenously once to 6 animals in each group at a volume of 10 mL / kg. The solvent control group was administered 0.9% sodium chloride injection, and observation was performed for 13 days after administration to compare the inhibitory effects of the three antibody-drug conjugates in the table on HER2-expressing human breast cancer JIMT-1 nude mouse tumors.

[0208] 5. Observation Indicators 5.1 Evaluation index

number

[0209] 6 results 6.1 Tumor volume At the end of the study, DP001-DXD ADC (DAR=4.3) (P <0.05), DP001-JSSW-001 ADC (DAR=4.0) (P <0.01), and DP001-ZW-002 ADC (DAR=5.78) (P <0.05) were able to significantly inhibit the volume of transplanted tumors compared with the vehicle group, as shown in Figure 13 and Table 5 in detail. [Table 6]

[0210] Study 3: Efficacy study of antibody-drug conjugates against human lung adenocarcinoma PC9-GR (gefitinib-resistant cells) cell-transplanted tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 16 mice

[0211] 2. Purpose of the study The in vivo antitumor effects of two patritumab-ADC drugs were examined using a human lung adenocarcinoma PC-9 / GR (gefitinib-resistant cells) cell NU / NU mouse xenograft tumor model.

[0212] 3. Drug Dosage and Grouping [Table 7]

[0213] 4. Test Method In this study, a nude mouse tumor model was established using human lung adenocarcinoma PC9-GR (gefitinib-resistant cells), and the tumor volume was approximately 110 mm 3When the tumor volume reached 100 mg / kg, the animals were divided into three groups (d0) according to the tumor volume, as shown in Table 6. Six animals were assigned to the vehicle group, and five animals were assigned to the patritumab-DXD ADC (DAR=7.3) group and the patritumab-JSSW-001 ADC (DAR=7.36) group. The animals were intravenously administered once a week for 4 consecutive weeks, with an administration volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the study was terminated 28 days after administration. The inhibitory effects of patritumab-DXD ADC (DAR=7.3) and patritumab-JSSW-001 ADC (DAR=7.36) on human lung adenocarcinoma PC9-GR (gefitinib-resistant cells) tumors transplanted into nude mice were compared.

[0214] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0215] 6 results 6.1 Tumor volume At the end of the study, the patritumab-JSSW-001 ADC (DAR=7.36) group (P <0.001) had a better tumor volume inhibition effect than the patritumab-DXD ADC (DAR=7.3) (P <0.01) group, as shown in Figure 14 and Table 7 in detail. [Table 8]

[0216] Study 4. Efficacy study of SWY2110-ADC against human colorectal cancer DiFi cell xenograft tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 14 mice

[0217] 2. Purpose of the study The in vivo antitumor effects of two SWY2110-ADC drugs were examined using a human colorectal cancer DiFi cell NU / NU mouse xenograft tumor model.

[0218] 3. Drug Dosage and Grouping [Table 9]

[0219] 4. Test Method In this study, a nude mouse tumor model was established using human colorectal cancer DiFi cells, and the tumor volume was approximately 110 mm 3 When the tumor volume reached 100 mg / kg, the animals were divided into three groups (d0) according to the tumor volume as shown in Table 8. Five animals were assigned to each of the vehicle group and SWY2110-JSSW-001 ADC (DAR=7.12), and four animals were assigned to the SWY2110-Vc MMAE ADC (DAR=4.53) group. A single intravenous administration was performed at an administration volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the animals were observed for 27 days after administration. The inhibitory effects of the two SWY2110-ADCs in the table on human colorectal cancer DiFi nude mouse transplanted tumors were compared.

[0220] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0221] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, both SWY2110-Vc MMAE ADC (DAR=4.53) (P<0.05) and SWY2110-JSSW-001 ADC (DAR=7.12) (P<0.05) showed significant tumor volume inhibition effects. The SWY2110-JSSW-001 ADC (DAR=7.12) group had a high tumor inhibition rate of 74.6% at 27 days, while the SWY2110-Vc MMAE ADC (DAR=4.53) had a slightly lower tumor inhibition rate of 69.7%. The lower toxicity of the small molecule JSSW-001 compared with Vc MMAE suggests that SWY2110-JSSW-001 ADC (DAR=7.12) achieved a more efficient and less toxic effect. Details are shown in Figure 15 and Table 9. [Table 10]

[0222] Study 5. Efficacy study of SWY2110-ADC against human lung adenocarcinoma PC9-GR (gefitinib-resistant cells) cell-transplanted tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 30 mice

[0223] 2. Purpose of the study The in vivo antitumor effects of SWY2110 monoclonal antibody and three SWY2110-ADC drugs were examined using a human lung adenocarcinoma PC-9-GR (gefitinib-resistant cells) cell xenograft tumor model in NU / NU mice.

[0224] 3. Drug Dosage and Grouping [Table 11]

[0225] 4. Test Method In this study, a nude mouse tumor model was established using human lung adenocarcinoma PC-9-GR (gefitinib resistant) cells, and the tumor volume was approximately 110 mm 3 When the tumor volume reached 100 mg / kg, the animals were divided into 5 groups (d0) according to the tumor volume, as shown in Table 10. Each group had 6 animals, and the tumor was administered intravenously once a week for 4 consecutive weeks at a volume of 10 mL / kg. The solvent control group was administered 0.9% sodium chloride injection, and the test was terminated 28 days after administration. The inhibitory effects of SWY2110 monoclonal antibody and three SWY2110-ADC drugs on human lung adenocarcinoma PC-9-GR (gefitinib-resistant cells) tumors transplanted into nude mice were compared.

[0226] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0227] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, the SWY2110-Vc MMAE ADC (DAR = 4.53) (P < 0.05), SWY2110-DXD ADC (DAR = 6.93) (P < 0.05), and SWY2110-JSSW-001 ADC (DAR = 7.12) (P < 0.001) all showed inhibitory effects on transplanted tumor volume. The tumor inhibition effect of the antibody SWY2110 was poor, with a tumor inhibition rate of only 20.3%. SWY2110-JSSW-001 ADC (DAR = 7.12) had the greatest inhibition effect on the transplanted tumor volume of PC9-GR, with a tumor inhibition rate of 77.7%. SWY2110-Vc MMAE ADC (DAR = 4.53) and SWY2110-DXD ADC (DAR = 6.93) had tumor inhibition rates of 40.4% and 50.2%, respectively. SWY2110-JSSW-001 ADC (DAR = 7.12) had a tumor inhibition effect against PCR-GR that was 154% of that of SWY2110-DXD ADC (DAR = 6.93). SWY2110-JSSW-001 ADC (DAR = 7.12) had a tumor inhibition effect against PCR-GR that was 154% of that of SWY2110-Vc MMAE ADC (DAR = 6.93). This was 192% of the ADC (DAR = 4.53), suggesting that the SWY2110-JSSW-001 ADC (DAR = 7.12) still had a significant inhibitory effect on gefitinib-resistant tumor cells. Details are shown in Figure 16 and Table 11. [Table 12]

[0228] Test 6. In vitro plasma stability of antibody-drug DP001-DXD ADC (DAR = 7.0), DP001-JSSW-001 ADC (DAR = 7.32) and DP001-ZW-002 ADC (DAR = 5.78) were incubated with 0.5% BSA-PBS and ICR mouse plasma, respectively, at incubation concentrations of DP001-DXD ADC (DAR = 7.0) (91.7 μg / mL), DP001-JSSW-001 ADC (DAR = 7.32) (80 μg / mL) and DP001-ZW-002 ADC (DAR = 5.78) (80 μg / mL). After incubation at 0, 24, 48, 72, 96, 120, 144, 168, 336 and 504 hours at 37°C under sterilization, samples were collected and the apheresis molecule concentrations in the plasma samples were detected using LC-MS / MS, with the results being as follows: [Table 13]

[0229] The results showed that the ADC demonstrated free small molecule generation in both 0.5% BSA-PBS and ICR mouse plasma when incubated at 37°C at 0, 24, 48, 72, 96, 120, 144, 168, 336, and 504 hours. After 504 hours of incubation, the apheresis rates in 0.5% BSA-PBS were DP001-DXD ADC (DAR=7.0) (3.90%), DP001-JSSW-001 ADC (DAR=7.32) (1.09%) and DP001-ZW-002 ADC (DAR=5.78) (2.91%), respectively, and in ICR mouse plasma, the apheresis rates were DP001-DXD ADC (DAR=7.0) (4.07%) and DP001-JSSW-001 ADC (DAR=7.32) (2.75%), respectively. In 0.5% BSA-PBS, the apheresis rates of antibodies to small molecules were all less than 4.0%, with DP001-DXD ADC (DAR=7.0)>DP001-ZW-002 ADC (DAR=5.78)>DP001-JSSW-001ADC (DAR=7.32), indicating that DP001-JSSW-001ADC (DAR=7.32) and DP001-ZW-002 ADC (DAR=5.78) were more stable in 0.5% BSA-PBS. The apheresis rates of antibodies and small molecules in ICR mouse plasma were all less than 5.0%, with DP001-DXD ADC (DAR=7.0) > DP001-JSSW-001ADC (DAR=7.32), indicating that DP001-JSSW-001ADC (DAR=7.32) was more stable in ICR mouse plasma than DP001-DXD ADC (DAR=7.0).

[0230] Study 7: Antibody-drug bystander effect study in vitro For the bystander effect test, first, positive cell line SK-BR-3 and negative control cell MDA-MB-468 were used to incubate with DP001-DXD ADC (DAR=7.0) and DP001-JSSW-001 ADC (DAR=7.32), respectively, and the released small molecule toxin could induce apoptosis of the surrounding negative cells in the co-culture, i.e., bystander effect. In this test, reporter gene cell HEK293-Luc was mainly co-incubated with positive cell line SK-BR-3 and negative control cell MDA-MB-468 for 4 days, respectively, and then the effect of the released small molecule toxin on HEK293-Luc proliferation was determined by adding a chemiluminescent substrate. The results showed that DP001-DXD ADC (DAR=7.0) and DP001-JSSW-001 ADC (DAR=7.32) entered the cells via endocytosis after binding to the HER2 receptor on the surface of tumor cells, and released the small molecule toxin into the cells, while DP001-JSSW-001 ADC (DAR=7.32) showed a stronger inhibitory effect on the proliferation of bystander cells.

[0231] 2. Exam Preparation [Table 14]

[0232] 3. Test Method 3.1 Reagent preparation 3.1.1 Preparation of cell resuscitation medium DMEM complete medium: 10% Fetal Bovine Serum and 1% Penicilin / Streptomycin were added to DMEM basal medium as the final system, mixed thoroughly, and then stored at 2 to 8°C. 3.1.2 Preparation of cell culture medium (containing screening agents) 10% Fetal Bovine Serum and 1% Penicilin / Streptomycin were added to the DMEM basal medium as the final system, and 200 μg / ml G418 was added. After thorough mixing, the mixture was stored at 2 to 8°C. 3.2 Cell preparation 3.2.1 Cell resuscitation The cell cryopreservation tube was placed in a water bath at 37°C, shook rapidly to completely dissolve, and then transferred to an ultra-clean bench or biological safety cabinet. The cell suspension was diluted with cell resuscitation medium, centrifuged, the centrifugal supernatant was discarded, and the cells were resuspended using cell resuscitation medium to measure cell density and viability. After adjusting the cell density with cell medium and mixing evenly, the cell suspension was transferred to a cell culture flask, and after checking for errors by microscopic examination, it was transferred to an incubator and cultured at 37°C and CO2. 3.2.2 Cell passaging The cell culture flask was removed from the CO2 incubator and transferred to an ultra-clean bench or biological safety cabinet, washed with PBS, digested with pancreatin, and after the digestion of the cell growth medium was completed, the cell suspension was collected and the cell density and viability were measured. An appropriate amount of the cell suspension was added to fresh medium (with or without screening agents) and passage expansion was performed according to the cell growth characteristics and test conditions. After passage, the cells were placed in the incubator to continue the culture. 3.3 Testing methods for the bystander effect 3.3.1 When the cells reach 90% confluency, harvest the SK-BR-3, MDA-MB-468 and HEK293-Luc cells by digestion with pancreatin, and resuspend the cells using the corresponding medium. 3.3.2 Resuspend the cells by gently blowing them off several times to prepare a single cell suspension. Measure the cell viability and cell number using trypan blue staining method. The cell density was 2.0 x 10 5 Adjust to cells / ml. 3.3.3 The density-adjusted SK-BR-3 and MDA-MB-468 cells were mixed with HEK293-Luc cell suspension at 1:1 ratio and added to a 96-well clear flat-bottom plate at 50 μl per well. The positive cell group was the mixed cells of SK-BR-3 and HEK293-Luc, and the negative cell group was the mixed cells of MDA-MB-468 and HEK293-Luc. 3.3.4 For the treatment groups of DP001-DXD ADC (DAR=7.0) and DP001-JSSW-001 ADC (DAR=7.32), three concentrations were set at final concentrations of 100 ng / mL, 500 ng / mL, and 1000 ng / mL, respectively, and 50 μl per well was added to the 96-well clear flat-bottom plate seeded with cells, and then incubated at 37°C in a CO2 incubator for 4 days. 3.3.5 After the incubation was finished, the culture plate was removed from the incubator, the temperature was restored to room temperature, and Bright-Glo® Luciferase Assay System was added to the culture plate at 100 μL / well, and the plate was read for chemiluminescence after being shielded from light for 5-15 minutes.

[0233] 4. Test results: DP001-DXD (DAR=7.0) and DP001-JSSW-001 ADC (DAR=7.32) entered the cells via endocytosis after binding to the HER2 receptor on the surface of tumor cells, and released small molecule toxins into the cells. Meanwhile, DP001-JSSW-001 ADC (DAR=7.32) showed a stronger inhibitory effect on the proliferation of bystander cells than DP001-DXD ADC (DAR=7.0). The test results are shown in Table 13 and Figure 19. [Table 15]

[0234] Test 8. Stability Testing of Linker-Drug Compounds Various linker-drug compounds, e.g., Deruxtecan, JSSW-001 and ZW-002 compounds, were subjected to high temperature (40°C, 60°C), high humidity (25°C / 75% RH and 25°C / 92.5% RH), light irradiation (illuminance 4500 Lux, near-ultraviolet energy 90 μw / cm 2) or 0.5% BSA-PBS, and samples were collected at different times after being left under different conditions, and the concentration changes of the linker-drug compounds in the samples were detected using LC-MS / MS. The test results showed that JSSW-001 and ZW-002 compounds showed better stability.

[0235] Study 9: Efficacy study of SWY2110-ADC against human lung adenocarcinoma PC9-AR (PC9-Del19 / T790M / C797S, Osimertinib-resistant cells) cell transplant tumors 1. Test Animals Balb / c nude mice, 5-6 weeks old, 24 mice

[0236] 2. Purpose of the study The in vivo antitumor effects of three SWY2110-ADC drugs were examined using a human lung adenocarcinoma PC9-Del19 / T790M / C797S (osimertinib-resistant cells, hereafter referred to as PC9-AR) cell xenograft tumor model in NU / NU mice.

[0237] 3. Drug Dosage and Grouping [Table 16]

[0238] 4. Test Method In this study, a nude mouse tumor model was established using human lung adenocarcinoma PC9-Del19 / T790M / C797S (osimertinib-resistant cells), and the tumor volume was approximately 110 mm 3 When the tumor volume reached 100 μg / kg, the animals were divided into 4 groups (d0) according to the tumor volume as shown in Table 14. Each group had 6 animals, and the tumor was intravenously administered once at a volume of 10 mL / kg. The solvent control group was administered 0.9% sodium chloride injection, and the test was terminated 24 days after administration. The inhibitory effects of the three SWY2110-ADC drugs on human lung adenocarcinoma PC9-Del19 / T790M / C797S (Osimertinib-resistant cells) tumors transplanted into nude mice were compared.

[0239] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0240] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, the SWY2110-Vc MMAE ADC (DAR = 4.53) (P < 0.001), SWY2110-Dxd ADC (DAR = 6.93) (P < 0.001) and SWY2110-JSSW-001 ADC (DAR = 7.12) (P < 0.001) all showed inhibitory effects on transplanted tumor volume. The SWY2110-JSSW-001 ADC (DAR = 7.12) group had the greatest inhibitory effect on the volume of transplanted PC9-GR tumors, with a high tumor inhibition rate of 97.5%. The tumor inhibition rates of the SWY2110-Vc MMAE ADC (DAR = 4.53) and SWY2110-DXD ADC (DAR = 6.93) were 89.7% and 76.2%, respectively. The tumor inhibition rate of the SWY2110-JSSW-001 ADC (DAR = 7.12) was 128% of that of the SWY2110-DXD ADC (DAR = 6.93), and the tumor inhibition rate of the SWY2110-JSSW-001 ADC (DAR = 7.12) was 109% of that of the SWY2110-Vc MMAE ADC (DAR = 4.53). It was suggested that ADC (DAR=7.12) still had a significant inhibitory effect on osimertinib-resistant tumor cells. The details are shown in FIG. 20 and Table 15. [Table 17]

[0241] Study 10: Efficacy study of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC against human lung adenocarcinoma NCI-H1975 (human lung adenocarcinoma cell) cell transplant tumors 1. Test Animals NU / NU mice, 5-6 weeks old, 30 mice

[0242] 2. Purpose of the study The in vivo antitumor effects of SWY2110-JSSW-001, SWY2111-JSSW-001, SWY2112-JSSW-001, and SWY2113-JSSW-001 were examined using a human lung adenocarcinoma NCI-H1975 (human lung adenocarcinoma cell) cell xenograft tumor model in NU / NU mice.

[0243] 3. Drug Dosage and Grouping [Table 18]

[0244] 4. Test Method This study used human lung adenocarcinoma NCI-H1975 cells to establish a nude mouse tumor model, with the tumor volume reaching approximately 110 mm 3 When the tumor volume reached 100 μg / kg, the animals were divided into 6 groups (d0) on average according to the tumor volume as shown in Table 16, and each group had 6 animals, and each group was administered with 1 mg / kg once. The administration was intravenously once at a volume of 10 mL / kg, and the vehicle control group was administered 0.9% sodium chloride injection, and the study was terminated 21 days after administration. The inhibitory effects of SWY2110-JSSW-001, SWY2111-JSSW-001, SWY2112-JSSW-001, and SWY2113-JSSW-001 on human lung adenocarcinoma NCI-H1975 tumors transplanted into nude mice were compared.

[0245] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0246] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, SWY2110-JSSW-001 ADC (DAR=7.12), SWY2112-JSSW-001 ADC (DAR=7.51), SWY2111-JSSW-001 ADC (DAR=7.48), and SWY2113-JSSW-001 ADC (DAR=7.50) (P <0.001) all showed excellent tumor inhibition effects, with tumor inhibition rates reaching 84.1%, 83.0%, 80.9%, and 74.2%, respectively (P <0.001). All four ADCs showed significant inhibition effects against human lung adenocarcinoma NCI-H1975 tumor cells. Details are shown in Figure 21 and Table 17. [Table 19]

[0247] Study 11: Efficacy study of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC against human breast cancer MDA-MB-468 (human breast cancer cell) cell transplant tumors 1. Test Animals NOD-SCID mice, 5-6 weeks old, 28 mice

[0248] 2. Purpose of the study The in vivo antitumor effects of SWY2110-JSSW-001, SWY2111-JSSW-001, SWY2112-JSSW-001, and SWY2113-JSSW-001 were examined using a NOD-SCID mouse tumor model implanted with human breast cancer MDA-MB-468 (human breast cancer cells).

[0249] 3. Drug Dosage and Grouping [Table 20]

[0250] 4. Test Method This study used human breast cancer MDA-MB-468 cells to establish a mouse tumor model with a tumor volume of approximately 150 mm 3When the tumor volume reached 100 μg / kg, the animals were divided into 5 groups (d0) according to the tumor volume as shown in Table 18. The control group had 8 animals, and the test group had 5 animals. The tumor volume was 10 mL / kg, and the vehicle control group was administered 0.9% sodium chloride injection. The test was terminated 28 days after administration. The in vivo antitumor effects of the four ADC drugs were examined.

[0251] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0252] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, SWY2110-JSSW-001 ADC (DAR=7.12), SWY2111-JSSW-001 ADC (DAR=7.48), SWY2112-JSSW-001 ADC (DAR=7.51), and SWY2113-JSSW-001 ADC (DAR=7.50) (P <0.001) all showed excellent tumor inhibition effects, with tumor inhibition rates reaching 65.8%, 65.1%, 58.3%, and 47.1%, respectively (P <0.001). All four ADCs showed significant inhibition effects against human breast cancer MDA-MB-468 tumor cells. Details are shown in Figure 22 and Table 19. [Table 21]

[0253] Study 12: Efficacy study of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC against human colorectal cancer DiFi (human colorectal cancer cell) cell transplant tumors 1. Test Animals NU / NU mice, 5-6 weeks old, 35 mice

[0254] 2. Purpose of the study The in vivo antitumor effects of SWY2110-JSSW-001, SWY2111-JSSW-001, SWY2112-JSSW-001, and SWY2113-JSSW-001 were examined using a colorectal cancer DiFi (human colorectal cancer cell) NU / NU mouse xenograft tumor model.

[0255] 3. Drug Dosage and Grouping [Table 22]

[0256] 4. Test Method This study used human colorectal cancer DiFi cells to establish a mouse tumor model, with tumor volumes of approximately 100 mm. 3 When the tumor volume reached 100 μg / kg, the animals were divided into 5 groups (d0) according to the tumor volume as shown in Table 20, and each group had 7 animals, and the tumor was intravenously administered twice at a volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the test was terminated 21 days after administration. The in vivo antitumor effects of the four ADC drugs were examined.

[0257] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0258] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, SWY2110-JSSW-001 ADC (DAR=7.12), SWY2111-JSSW-001 ADC (DAR=7.48), SWY2112-JSSW-001 ADC (DAR=7.51), and SWY2113-JSSW-001 ADC (DAR=7.50) all showed excellent tumor inhibition effects, with tumor inhibition rates reaching 86.5%, 82.3%, 83.5%, and 76.8%, respectively (P <0.001). All four ADCs showed significant inhibition effects against human colorectal cancer DiFi tumor cells. Details are shown in Figure 23 and Table 21. [Table 23]

[0259] Study 13: Efficacy study of SWY2110-ADC, SWY2111-ADC, SWY2112-ADC, and SWY2113-ADC against human lung adenocarcinoma PC9-GR (human lung adenocarcinoma gefitinib-acquired drug resistance line) cell transplant tumors 1. Test Animals NU / NU mice, 5-6 weeks old, 30 mice

[0260] 2. Purpose of the study The in vivo antitumor effects of SWY2110-JSSW-001, SWY2111-JSSW-001, SWY2112-JSSW-001, and SWY2113-JSSW-001 were examined using a human lung adenocarcinoma cell PC9-GR NU / NU mouse xenograft tumor model.

[0261] 3. Drug Dosage and Grouping [Table 24]

[0262] 4. Test Method This study used human lung adenocarcinoma PC9-GR cells to establish a mouse tumor model with a tumor volume of approximately 110 mm 3 When the tumor volume reached 100 μg / kg, the animals were divided into 5 groups (d0) according to the tumor volume as shown in Table 22, and each group had 6 animals, and the tumor was intravenously administered once at a volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the test was terminated 28 days after administration. The in vivo antitumor effects of the four ADC drugs were examined.

[0263] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0264] 6 results 6.1 Tumor volume At the end of the study, compared with the vehicle group, SWY2110-JSSW-001 ADC (DAR=7.12), SWY2111-JSSW-001 ADC (DAR=7.48), SWY2112-JSSW-001 ADC (DAR=7.51), and SWY2113-JSSW-001 ADC (DAR=7.50) all showed excellent tumor inhibition effects, with tumor inhibition rates reaching 99.0%, 100.1%, 92.4%, and 89.3%, respectively (P <0.001). All four ADCs showed significant inhibition effects against human lung adenocarcinoma PC9-GR tumor cells. Details are shown in Figure 24 and Table 23. [Table 25]

[0265] Study 14: Efficacy study of antibody-drug conjugates against transplanted human lung adenocarcinoma PC9-DTC (Del19 / T790M / C797S, Osimertinib-resistant cells) tumors in NOD-SCID mice 1. Test Animals NOD-SCID mice, 5-6 weeks old, 18 mice

[0266] 2. Purpose of the study The in vivo antitumor effects of two patritumab-ADC drugs were examined using a human lung adenocarcinoma PC9-DTC (Del19 / T790M / C797S, Osimertinib-resistant cells) cell xenograft tumor model in NU / NU mice.

[0267] 3. Drug Dosage and Grouping [Table 26]

[0268] 4. Test Method This study used human lung adenocarcinoma PC9-DTC (Del19 / T790M / C797S, osimertinib-resistant cells) cells to establish a nude mouse tumor model, with the tumor volume reaching approximately 115 mm 3When the tumor volume reached 100 mg / kg, the animals were divided into three groups (d0) according to the tumor volume as shown in Table 24. Six animals were assigned to each of the vehicle group, patritumab-DXD ADC (DAR=7.3) group, and patritumab-JSSW-001 ADC (DAR=7.36) group, and the animals were intravenously administered once a week for three consecutive weeks at a dose volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the test was terminated 26 days after administration. The inhibitory effects of patritumab-DXD ADC (DAR=7.3) and patritumab-JSSW-001 ADC (DAR=7.36) on human lung adenocarcinoma PC9-DTC (Del19 / T790M / C797S, Osimertinib-resistant cells) tumors transplanted into nude mice were examined.

[0269] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0270] 6 results 6.1 Tumor volume At the end of the study, the patritumab-JSSW-001 ADC (DAR=7.36) group (P<0.001) had a better inhibitory effect on transplanted tumor volume than the patritumab-DXD ADC (DAR=7.3) (P<0.001) group. Details are shown in Figure 25 and Table 25. [Table 27]

[0271] Study 15. Efficacy study of antibody-drug conjugates against human colon cancer SW620 cell-implanted tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 18 mice

[0272] 2. Purpose of the study The in vivo antitumor effects of two patritumab-ADC drugs were examined using a human colon cancer SW620 cell NU / NU mouse xenograft tumor model.

[0273] 3. Drug Dosage and Grouping [Table 28]

[0274] 4. Test Method This study used human colon cancer SW620 cells to establish a nude mouse tumor model, with the tumor volume reaching approximately 110 mm. 3 When the tumor volume reached 100 mg / kg, the animals were divided into three groups (d0) according to the tumor volume as shown in Table 26. Six animals were assigned to each of the vehicle group, patritumab-DXD ADC (DAR=7.3) group, and patritumab-JSSW-001 ADC (DAR=7.36) group, and the animals were intravenously administered once at a volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the test was terminated 26 days after administration. The inhibitory effects of patritumab-DXD ADC (DAR=7.3) and patritumab-JSSW-001 ADC (DAR=7.36) on human colon cancer SW620 tumors transplanted into nude mice were compared.

[0275] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0276] 6 results 6.1 Tumor volume At the end of the study, the patritumab-JSSW-001 ADC (DAR=7.36) group (P<0.001) had a better inhibitory effect on transplanted tumor volume than the patritumab-DXD ADC (DAR=7.3) (P<0.001) group. Details are shown in Figure 26 and Table 27. [Table 29]

[0277] Study 16. Efficacy study of antibody-drug conjugates against human colon cancer DiFi cell xenograft tumors in NU / NU mice 1. Test Animals NU / NU mice, 5-6 weeks old, 18 mice

[0278] 2. Purpose of the study The in vivo antitumor effects of two patritumab-ADC drugs were examined using a colorectal cancer DiFi cell NU / NU mouse xenograft tumor model.

[0279] 3. Drug Dosage and Grouping [Table 30]

[0280] 4. Test Method This study used human colorectal cancer DiFi cells to establish a nude mouse tumor model, with tumor volumes of approximately 110 mm. 3 When the tumor volume reached 100 μg / kg, the animals were divided into three groups (d0) according to the tumor volume as shown in Table 28. There were 6 animals in the vehicle group, and 5 animals each in the patritumab-DXD ADC (DAR=7.3) group and the patritumab-JSSW-001 ADC (DAR=7.36) group. The animals were intravenously administered once, with a dose volume of 10 mL / kg. The vehicle control group was administered 0.9% sodium chloride injection, and the study was terminated 28 days after administration. The inhibitory effects of patritumab-DXD ADC (DAR=7.3) and patritumab-JSSW-001 ADC (DAR=7.36) on human colorectal cancer DiFi nude mouse transplanted tumors were compared.

[0281] 5. Observation Indicators 5.1 Evaluation index See 5.1 Evaluation Index in Study 2

[0282] 6 results 6.1 Tumor volume At the end of the study, the patritumab-JSSW-001 ADC (DAR=7.36) group (P<0.001) had a better inhibitory effect on transplanted tumor volume than the patritumab-DXD ADC (DAR=7.3) (P<0.001) group. Details are shown in Figure 27 and Table 29. [Table 31]

[0283] Test 17: Safety Test In this study, six aged cynomolgus monkeys were used, half of which were male and half of which were female, and SWY2110-JSSW-001, SWY2111-JSSW-001, and SWY2113-JSSW-001 were administered intravenously. The dosage design is shown in the table below. Three consecutive intravenous injections were administered every three weeks, and the mice were observed continuously for seven days after administration, with general observation twice a day and detailed observation once a day. The changes in body weight were observed before and after administration, and hematological tests were performed. The experimental results showed that SWY2110-JSSW-001 had reduced toxicity in the skin and gastrointestinal tract compared to ADCs prepared with pH-dependent antibodies (SWY2111-JSSW-001 and SWY2113-JSSW-001), and no significant target-related toxicity (skin bruising, scabs, dilute stool, etc.) occurred. Although the ADCs prepared by pH denaturation were found to have reduced toxicity to normal tissues, there was no significant differentiation in hematologic toxicity of the three ADC small molecules.

[0284] [Table 32] [Table 33]

Claims

1. An antibody-drug conjugate of formula I or formula II, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, [Formula 1] where Ab is an antibody or antigen-binding fragment thereof that targets HER2, HER3, or EGFR; R is C 1-6 alkyl, and n is selected from an integer of 1 to 8 or a decimal point of 1 to 8.

2. The antibody-drug conjugate of claim 1, wherein formula I is further formula Ia or formula Ib, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, [Case 2] In Formula Ia and Formula Ib, Ab, R and n are defined as in Formula I.

3. The antibody-drug conjugate of claim 1, wherein formula I is further represented by formula I-1, formula Ia-1 or formula Ib-1, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, [C3] In formula I-1, formula Ia-1 and formula Ib-1, Ab and n are defined as in formula I.

4. The antibody-drug conjugate according to any one of claims 1 to 3, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotopic derivative thereof, When the Ab is an antibody or antigen-binding fragment thereof targeting HER2, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the sequence of the heavy chain variable region comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3), the sequence of the light chain variable region comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), the amino acid sequence of HCDR1 is set forth in SEQ ID NO:1, the amino acid sequence of HCDR2 is set forth in SEQ ID NO:2, the amino acid sequence of HCDR3 is set forth in SEQ ID NO:3, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO:4, the amino acid sequence of LCDR2 is set forth in SEQ ID NO:5 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO:6; More preferably, when the Ab is an antibody or an antigen-binding fragment thereof targeting HER2, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the amino acid sequence of the HV being shown in SEQ ID NO: 7, and the amino acid sequence of the LV being shown in SEQ ID NO: 8; More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER2, it comprises a heavy chain (HC) and a light chain (LC), the amino acid sequence of the HC being set forth in SEQ ID NO: 9 and the amino acid sequence of the LC being set forth in SEQ ID NO: 10; When the Ab is an antibody or antigen-binding fragment thereof targeting HER3, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the heavy chain variable region sequence comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3), the light chain variable region comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), the amino acid sequence of HCDR1 is set forth in SEQ ID NO: 11, the amino acid sequence of HCDR2 is set forth in SEQ ID NO: 12, the amino acid sequence of HCDR3 is set forth in SEQ ID NO: 13, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO: 14, the amino acid sequence of LCDR2 is set forth in SEQ ID NO: 15 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO: 16; More preferably, when the Ab is an antibody or an antigen-binding fragment thereof targeting HER3, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the amino acid sequence of the HV being shown in SEQ ID NO: 17, and the amino acid sequence of the LV being shown in SEQ ID NO: 18; More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting HER3, it comprises a heavy chain (HC) and a light chain (LC), the amino acid sequence of the HC being set forth in SEQ ID NO: 19 and the amino acid sequence of the LC being set forth in SEQ ID NO: 20; When the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the heavy chain variable region sequence comprises heavy chain complementarity determining region 1 (HCDR1), heavy chain complementarity determining region 2 (HCDR2) and heavy chain complementarity determining region 3 (HCDR3), the light chain variable region comprises light chain complementarity determining region 1 (LCDR1), light chain complementarity determining region 2 (LCDR2) and light chain complementarity determining region 3 (LCDR3), the amino acid sequence of HCDR1 is set forth in SEQ ID NO:21 or SEQ ID NO:31 or SEQ ID NO:35 or SEQ ID NO:38, the amino acid sequence of HCDR2 is set forth in SEQ ID NO:22, the amino acid sequence of HCDR3 is set forth in SEQ ID NO:23 or SEQ ID NO:32, and / or the amino acid sequence of LCDR1 is set forth in SEQ ID NO:24, the amino acid sequence of LCDR2 is set forth in SEQ ID NO:25 and the amino acid sequence of LCDR3 is set forth in SEQ ID NO:26; More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain variable region (HV) and a light chain variable region (LV), the amino acid sequence of the HV is shown in SEQ ID NO: 27 or SEQ ID NO: 33 or SEQ ID NO: 36 or SEQ ID NO: 39, and the amino acid sequence of the LV is shown in SEQ ID NO: 28; More preferably, when the Ab is an antibody or antigen-binding fragment thereof targeting EGFR, it comprises a heavy chain (HC) and a light chain (LC), the amino acid sequence of the HC being set forth in SEQ ID NO:29 or SEQ ID NO:34 or SEQ ID NO:37 or SEQ ID NO:40, and the amino acid sequence of the LC being set forth in SEQ ID NO:

30.

5. The antibody-drug conjugate according to any one of claims 1 to 4, wherein the antibody, preferably a monoclonal antibody, preferably the monoclonal antibody is selected from a human antibody, a humanized antibody, and a chimeric antibody, and a pharma-ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotopic derivative thereof.

6. The antigen-binding fragment is preferably Fab', (Fab') 2 5. The antibody-drug conjugate according to claim 1 , which is selected from the group consisting of Fab, Fv, scFv and dAb, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotopic derivative thereof.

7. A linker-drug compound having formula III, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof, [C4] In the formula, R is C 1-6 Alkyl, preferably C 1-3 It is preferably selected from alkyl, more preferably methyl, ethyl, propyl, isopropyl.

8. 8. The linker-drug compound of claim 7, wherein formula III is further selected from the group consisting of formula IIIa and formula IIIb, and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers, and isotopic derivatives thereof, [C5]

9. A linker-drug compound having the formula: and pharma- ceutically acceptable salts, hydrates, solvates, stereoisomers or isotopic derivatives thereof: [C6]

10. A pharmaceutical composition comprising the antibody-drug conjugate according to any one of claims 1 to 6, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotope derivative thereof.

11. Use of the antibody-drug conjugate according to any one of claims 1 to 6, and its pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotopic derivative, in the manufacture of a pharmaceutical for the treatment of a proliferative disease.

12. 12. The use according to claim 11, characterized in that the proliferative disease is a disease associated with abnormal expression of HER2, HER3 or EGFR, including cancer, preferably selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, sarcoma, lung cancer (e.g. small cell and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g. acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer or lymphoma (e.g. Hodgkin's lymphoma, non-Hodgkin's lymphoma or recurrent anaplastic large cell lymphoma).

13. Use of the antibody-drug conjugate according to any one of claims 1 to 6, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotope derivative thereof, in the manufacture of a pharmaceutical for the treatment of a proliferative disease which has developed drug resistance.

14. The proliferative disease causing drug resistance is a disease associated with abnormal expression of HER2, HER3 or EGFR causing drug resistance, including cancer, and the cancer causing drug resistance is preferably a drug-resistant cancer caused by a mutation in the HER2, HER3 or EGFR gene, and the cancer is preferably breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, gastric cancer, endometrial cancer, salivary gland cancer, esophageal cancer, melanoma, glioma, neuroblastoma, 14. The use according to claim 13, wherein the cancer is selected from the group consisting of alveolar cysts, sarcomas, lung cancer (e.g. small cell lung cancer and non-small cell lung cancer), colon cancer, rectal cancer, colorectal cancer, leukemia (e.g. acute lymphocytic leukemia, acute myeloid leukemia, acute promyelocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia), bone cancer, skin cancer, thyroid cancer, pancreatic cancer or lymphoma (e.g. Hodgkin's lymphoma, non-Hodgkin's lymphoma or recurrent anaplastic large cell lymphoma), more preferably colon cancer, rectal cancer, lung cancer or pancreatic cancer.

15. The use according to claim 13, wherein the drug resistance is resistance to a receptor tyrosine kinase inhibitor, more preferably resistance to a first, second or third generation EGFR inhibitor, even more preferably resistance to gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib or alumonatinib, in particular resistance to gefitinib, afatinib, osimertinib or alumonatinib, more preferably resistance to gefitinib or osimertinib.

16. A method for producing the antibody-drug conjugate according to any one of claims 1 to 6, and a pharma- ceutically acceptable salt, hydrate, solvate, stereoisomer, or isotope derivative thereof, comprising the steps of: S1: reduction of antibody; S2: Coupling of antibody to drug linker; S3: Purification of antibody-drug conjugates.

Citation Information

Patent Citations

  • Camptothecin drugs and antibody conjugates thereof

    CN111689980A

  • Bispecific recombinant proteins and their applications

    JP2020520249A

  • Deuterated camptothecin derivatives and antibody-drug conjugates thereof

    JP2023545580A

  • Ligand drug conjugates and their applications

    JP2024523524A

  • Antibody-Drug Conjugate

    US20180036423A1